Horizon Technology Finance (HRZN) 10-K 28 Feb 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Feb. 27, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 282,300,000
Entity Common Stock, Shares Outstanding		28,320,399
Auditor Firm ID	49
Auditor Name	RSM US LLP
Auditor Location	Hartford, Connecticut
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

Consolidated Statements of Asse

Consolidated Statements of Assets and Liabilities - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Investments at fair value	$ 720,026	$ 458,075
Cash	20,612	38,054
Investments in money market funds	7,066	7,868
Restricted investments in money market funds	2,788	1,359
Interest receivable	13,573	6,154
Other assets	2,761	2,450
Total assets	766,826	513,960
Liabilities
Borrowings (Note 7)	434,078	257,613
Distributions payable	9,159	6,365
Base management fee payable (Note 3)	1,065	706
Incentive fee payable (Note 3)	1,392	2,015
Other accrued expenses	2,684	1,926
Total liabilities	448,378	268,625
Commitments and contingencies (Notes 3, 8 and 9)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 27,920,838 and 21,384,925 shares issued and 27,753,373 and 21,217,460 shares outstanding as of December 31, 2022 and December 31, 2021, respectively	29	22
Paid-in capital in excess of par	385,921	301,359
Distributable earnings	(67,502)	(56,046)
Total net assets	318,448	245,335
Total liabilities and net assets	$ 766,826	$ 513,960
Net asset value per common share (in dollars per share)	$ 11.47	$ 11.56
Non-affiliate [Member]
Assets
Investments at fair value	$ 720,026	$ 458,075
Affiliate [Member]
Assets
Investments at fair value	$ 0	$ 0

Consolidated Statements of As_2

Consolidated Statements of Assets and Liabilities (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments at cost	$ 721,248	$ 453,837
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	27,920,838	21,384,925
Common stock, shares outstanding (in shares)	27,753,373	21,217,460
Non-affiliate [Member]
Investments at cost	$ 721,248	$ 452,387
Affiliate [Member]
Investments at cost	$ 0	$ 1,450

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment income
Interest income on investments	$ 77,366	$ 54,411	$ 42,192
Total fee income	1,825	5,604	3,725
Dividend income	0	0	118
Total investment income	79,191	60,015	46,035
Expenses
Interest expense	19,202	12,034	9,673
Base management fee (Note 3)	10,566	7,617	6,458
Performance based incentive fee (Note 3)	7,745	7,055	5,187
Administrative fee (Note 3)	1,667	1,285	1,016
Professional fees	1,650	1,892	1,540
General and administrative	1,459	1,511	1,190
Total expenses	42,289	31,394	25,064
Net investment income before excise tax	36,902	28,621	20,971
Provision for excise tax	715	401	222
Net investment income	36,187	28,220	20,749
Net realized and unrealized loss
Net realized (loss) gain on investments	(9,484)	(3,248)	(14,698)
Net realized loss on extinguishment of debt	0	(395)	0
Net realized loss	(9,484)	(3,643)	(14,698)
Net unrealized (depreciation) appreciation on investments	(5,552)	3,205	313
Net realized and unrealized loss	(15,036)	(438)	(14,385)
Net increase in net assets resulting from operations	$ 21,151	$ 27,782	$ 6,364
Net investment income per common share (in dollars per share)	$ 1.46	$ 1.41	$ 1.18
Net increase in net assets resulting from operations per common share (in dollars per share)	0.86	1.39	0.36
Distributions declared per share (in dollars per share)	$ 1.28	$ 1.25	$ 1.25
Weighted average shares outstanding (in shares)	24,726,079	20,027,420	17,534,528
Non-affiliate [Member]
Investment income
Interest income on investments	$ 77,366	$ 54,159	$ 41,503
Prepayment fee income on non-affiliate investments	1,568	4,111	2,345
Fee income on investments	257	1,481	1,335
Net realized and unrealized loss
Net realized (loss) gain on investments	(8,364)	(2,858)	(14,686)
Net unrealized (depreciation) appreciation on investments	(7,002)	5,503	1,585
Affiliate [Member]
Investment income
Interest income on investments	0	252	689
Fee income on investments	0	12	45
Dividend income	0	0	118
Non-controlled Affiliate [Member]
Net realized and unrealized loss
Net realized (loss) gain on investments	30	(390)	0
Net unrealized (depreciation) appreciation on investments	0	(848)	(1,014)
Controlled Affiliate [Member]
Net realized and unrealized loss
Net realized (loss) gain on investments	(1,150)	0	(12)
Net unrealized (depreciation) appreciation on investments	$ 1,450	$ (1,450)	$ (258)

Consolidated Statements of Chan

Consolidated Statements of Changes in Net Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock Outstanding [Member]
Balance (in shares)	21,217,460	19,286,356	15,563,290
Issuance of common stock, net of offering costs (in shares)	6,482,684	1,907,234	3,702,500
Issuance of common stock under dividend reinvestment plan (in shares)	53,229	23,870	20,566
Balance (in shares)	27,753,373	21,217,460	19,286,356
Common Stock [Member]
Balance	$ 22	$ 19	$ 16
Issuance of common stock, net of offering costs	7	3	3
Net investment income, net of excise tax	0	0	0
Net realized loss on investments	0	0	0
Unrealized Gain (Loss) on Investments	0	0	0
Issuance of common stock under dividend reinvestment plan	0	0	0
Distributions declared	0	0	0
Reclassification of permanent tax differences (Note 2)	0	0	0
Net realized loss on extinguishment of debt		0
Net unrealized appreciation on investments	0	0	0
Balance	29	22	19
Additional Paid-in Capital [Member]
Balance	301,359	271,287	226,660
Issuance of common stock, net of offering costs	84,596	30,083	44,608
Net investment income, net of excise tax	0	0	0
Net realized loss on investments	0	0	0
Unrealized Gain (Loss) on Investments	0	0	0
Issuance of common stock under dividend reinvestment plan	681	390	241
Distributions declared	0	0	0
Reclassification of permanent tax differences (Note 2)	(715)	(401)	(222)
Net realized loss on extinguishment of debt		0
Net unrealized appreciation on investments	0	0	0
Balance	385,921	301,359	271,287
Retained Earnings [Member]
Balance	(56,046)	(58,709)	(42,621)
Issuance of common stock, net of offering costs	0	0	0
Net investment income, net of excise tax	36,187	28,220	20,749
Net realized loss on investments	(9,484)	(3,248)	(14,698)
Unrealized Gain (Loss) on Investments	(5,552)	3,205	313
Issuance of common stock under dividend reinvestment plan	0	0	0
Distributions declared	(33,322)	(25,520)	(22,674)
Reclassification of permanent tax differences (Note 2)	715	401	222
Net realized loss on extinguishment of debt		(395)
Net unrealized appreciation on investments	(5,552)	3,205	313
Balance	(67,502)	(56,046)	(58,709)
Balance	245,335	212,597	184,055
Issuance of common stock, net of offering costs	84,603	30,086	44,611
Net investment income, net of excise tax	36,187	28,220	20,749
Net realized loss on investments	(9,484)	(3,248)	(14,698)
Unrealized Gain (Loss) on Investments	(5,552)	3,205	313
Issuance of common stock under dividend reinvestment plan	681	390	241
Distributions declared	(33,322)	(25,520)	(22,674)
Reclassification of permanent tax differences (Note 2)	0	0	0
Net realized loss on extinguishment of debt	0	(395)	0
Net unrealized appreciation on investments	(5,552)	3,205	313
Balance	$ 318,448	$ 245,335	$ 212,597

Consolidated Statements of Cash

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net increase in net assets resulting from operations	$ 21,151	$ 27,782	$ 6,364
Adjustments to reconcile net increase in net assets resulting from operations to net cash used in operating activities:
Amortization of debt issuance costs	1,604	1,091	1,018
Net realized loss on investments	9,484	3,248	14,698
Net realized loss on extinguishment of debt	0	395	0
Net unrealized depreciation (appreciation) on investments	5,552	(3,205)	(313)
Purchase of investments	(421,978)	(344,445)	(198,561)
Principal payments received on investments	95,871	188,010	146,258
Proceeds from sale of investments	49,964	52,954	8,335
Dividends from controlled affiliate investment	0	0	(118)
Equity received in settlement of fee income	0	0	(45)
Warrants received in settlement of fee income	0	0	(978)
Changes in assets and liabilities:
(Increase) decrease in interest receivable	(3,417)	(173)	887
Increase in end-of-term payments	(4,452)	(1,652)	(1,066)
Decrease in unearned income	(394)	(1,295)	(1,408)
Increase in other assets	(156)	(394)	(189)
Increase in other accrued expenses	758	509	430
Increase in base management fee payable	359	143	44
(Decrease) increase in incentive fee payable	(623)	1,040	(638)
Net cash used in operating activities	(246,277)	(75,992)	(25,282)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs	84,603	30,086	44,611
Advances on Credit Facilities	199,000	127,000	80,250
Repayment of Credit Facilities	(149,500)	(45,000)	(47,000)
Debt issuance costs	(4,364)	(2,645)	(890)
Distributions paid	(29,847)	(24,551)	(21,316)
Net cash provided by financing activities	229,462	75,515	55,655
Net (decrease) increase in cash, cash equivalents and restricted cash	(16,815)	(477)	30,373
Cash, cash equivalents and restricted cash:
Beginning of period	47,281	47,758	17,385
End of period	30,466	47,281	47,758
Supplemental disclosure of cash flow information:
Cash paid for interest	17,028	10,706	8,593
Supplemental non-cash investing and financing activities:
Refinanced debt investment balances	30,625	0	0
Warrant investments received and recorded as unearned income	5,616	3,355	1,829
Distributions payable	9,159	6,365	5,786
Acquisition of controlled affiliate investment	0	0	16,498
End-of-term payments receivable	9,690	5,238	4,203
Non-cash income	6,314	4,580	5,124
Cash	20,612	38,054	19,502
Investments in money market funds	7,066	7,868	27,199
Restricted investments in money market funds	2,788	1,359	1,057
Total cash, cash equivalents and restricted cash	30,466	47,281	47,758
The 2027 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of notes	57,500	0	0
The 2026 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of notes	0	57,500	0
Asset-backed Notes 2022 [Member]
Cash flows from financing activities:
Proceeds from issuance of notes	100,000	0	0
Asset-backed Notes 2019 [Member]
Cash flows from financing activities:
Repayment of notes	(27,930)	(29,500)	0
The 2022 Notes [Member]
Cash flows from financing activities:
Repayment of notes	$ 0	$ (37,375)	$ 0

Consolidated Schedule of Invest

Consolidated Schedule of Investments	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Investment Holdings, Schedule of Investments [Text Block]	Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,853 $ 2,777 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,823 2,750 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,411 1,374 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,891 4,891 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,962 1,962 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,963 1,963 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,923 4,923 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % May 1, 2026 5,000 4,912 4,912 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 10,000 9,872 9,872 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 15,000 14,808 14,808 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,476 2,476 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,473 2,473 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 5,000 4,857 4,857 Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,500 2,430 2,430 IMV Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,946 4,946 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,473 2,473 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,077 6,077 Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,177 6,177 Native Microbials, Inc (2) (12) Biotechnology Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,630 3,630 Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,469 2,469 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,701 9,701 Term Loan 13.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,697 3,697 Term Loan 13.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,697 3,697 Provivi, Inc. (2)(12) Biotechnology Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,597 4,597 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,597 4,597 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,280 2,280 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,280 2,280 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,274 2,274 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,274 2,274 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,914 4,914 Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,457 2,457 Aerobiotix, LLC (2)(12) Medical Device Term Loan 13.75 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,463 2,364 Term Loan 13.75 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,463 2,364 Canary Medical Inc. (2)(12) Medical Device Term Loan 12.75 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,475 2,475 Term Loan 12.75 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,489 2,489 Term Loan 12.75 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,473 2,473 Ceribell, Inc. (2)(12) Medical Device Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,973 4,973 Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,973 4,973 Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,478 2,478 Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,478 2,478 Cognoa, Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,466 2,466 Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,932 4,932 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 12.17 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,898 3,898 Term Loan 12.17 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,898 3,898 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 12.25 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 Term Loan 12.25 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 CSA Medical, Inc. (2)(12) Medical Device Term Loan 12.37 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 1,625 1,610 1,610 Term Loan 12.37 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 108 107 107 Term Loan 12.37 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 2,000 1,983 1,983 Embody, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 6.50 % 9.75 % - 28.00 % August 1, 2026 2,500 2,482 2,482 InfoBionic, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 3,208 3,143 3,143 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 974 974 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,939 4,939 Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,939 4,939 Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,933 4,933 Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,933 4,933 Term Loan 12.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,913 4,913 Term Loan 12.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,913 4,913 Robin Healthcare, Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,360 3,360 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,460 3,460 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,597 3,597 Term Loan 11.75 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,706 3,706 Sonex Health, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,476 2,476 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,476 2,476 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,476 2,476 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,453 2,453 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % May 1, 2026 2,500 2,455 2,455 Spineology, Inc. (2)(12) Medical Device Term Loan 14.50 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,966 4,966 Term Loan 14.50 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,481 2,481 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 12.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,349 3,349 Term Loan 12.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,454 3,454 Total Non-Affiliate Debt Investments — Life Science 318,172 317,568 Non-Affiliate Debt Investments — Sustainability — 26.3% Aerofarms, Inc. (2)(12) Other Sustainability Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,699 3,699 Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,699 3,699 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,371 7,371 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,371 7,371 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,371 7,371 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,903 4,903 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,903 4,903 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,463 2,463 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,927 4,927 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,924 4,924 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,462 2,462 Term Loan 13.00 % Prime 5.50 % 10.00 % - 2.75 % December 1, 2026 5,000 4,900 4,900 Term Loan 13.00 % Prime 5.50 % 10.00 % - 2.75 % December 1, 2026 2,500 2,450 2,450 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,697 3,697 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,717 3,717 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 7,500 7,424 7,424 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,712 3,712 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,712 3,712 Total Non-Affiliate Debt Investments — Sustainability 83,705 83,705 Non-Affiliate Debt Investments — Technology — 81.4% Axiom Space, Inc. (2)(12) Communications Term Loan 13.00 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,455 7,455 Term Loan 13.00 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,455 7,455 Term Loan 13.00 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,455 7,455 Convertible Note 3.00 % July 1, 2023 250 250 306 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,966 4,966 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,966 4,966 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 3,000 2,979 2,979 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % December 1, 2025 1,000 976 976 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % February 1, 2026 1,000 977 977 Better Place Forests Co. (2)(12)(13) Consumer-related Technologies Term Loan 13.75 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,000 4,951 3,834 Term Loan 13.75 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 1,916 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,461 3,461 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,482 2,482 Term Loan 12.75 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,482 2,482 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,478 3,478 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,238 1,238 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,715 3,715 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,238 1,238 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,715 3,715 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,238 1,238 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,698 3,698 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,698 3,698 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 12.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,082 1,082 Term Loan 12.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 1,623 1,623 Term Loan 11.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 11.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Interior Define, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 3,210 3,151 — Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 2,963 2,886 — Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 10.00 % Prime 6.75 % 10.00 % - - September 1, 2027 2,500 2,588 2,279 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 5,000 4,954 4,954 Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,500 2,477 2,477 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 5,000 4,943 4,715 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,000 1,981 1,890 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,477 2,363 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 3,000 2,971 2,835 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,459 2,345 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,459 2,345 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 5,000 4,914 4,688 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,456 2,342 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,347 2,347 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,700 2,673 2,673 Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,700 2,673 2,673 Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 3,000 2,967 2,967 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 7.75 % 11.00 % - - July 1, 2025 2,500 2,473 2,473 Term Loan 15.25 % Prime 7.75 % 11.00 % - - July 1, 2025 1,250 1,236 1,236 Term Loan 15.25 % Prime 7.75 % 11.00 % - - July 1, 2025 1,250 1,236 1,236 Liqid, Inc. (2)(12) Networking Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,333 3,286 3,286 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,333 3,286 3,286 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,667 1,641 1,641 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,667 1,641 1,641 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,667 1,613 1,613 BriteCore Holdings, Inc. (2)(12) Software Term Loan 13.75 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,421 2,421 Term Loan 13.75 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,487 2,487 Decisyon, Inc. (12) Software Term Loan 16.93 % Prime 9.43 % 12.68 % - 50.43 % December 31, 2022 3,295 3,295 3,295 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 14.00 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,347 6,347 Term Loan 14.00 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,859 5,859 Term Loan 14.00 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,436 2,436 Engage3, LLC (2)(12) Software Term Loan 13.25 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,678 3,678 Term Loan 13.25 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,718 3,718 Groundspeed Analytics, Inc. (2)(12) Software Term Loan 13.00 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,798 4,798 Term Loan 13.00 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,948 4,948 Kodiak Robotics, Inc. (2)(12) Software Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,826 9,826 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,826 9,826 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,913 4,913 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,913 4,913 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 14.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,947 4,947 Term Loan 14.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,474 2,474 Lytics, Inc. (2)(12) Software Term Loan 13.00 % Prime 6.00 % 9.25 % - 3.00 % July 1, 2025 2,500 2,396 2,396 Term Loan 13.00 % Prime 6.00 % 12.25 % - 3.00 % December 1, 2026 1,250 1,231 1,231 Reputation Institute, Inc. (2)(12) Software Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 5,000 4,932 4,932 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,870 4,870 Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,933 4,933 Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,933 4,933 Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,933 4,933 Supply Network Visiblity Holdings LLC (2)(12) Software Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,472 3,472 Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,472 3,472 Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,472 2,472 Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,472 2,472 Total Non-Affiliate Debt Investments — Technology 268,468 259,366 Non-Affiliate Debt Investments — Healthcare information and services — 8.1% Hound Labs inc. (2) (12) Diagnostics Term Loan 13.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,385 2,385 Term Loan 13.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,473 2,473 Term Loan 13.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,946 4,946 Secure Transfusion Services, Inc. (2)(12)(13) Other Healthcare Term Loan 13.25 % Prime 5.75 % 9.00 % - 4.00 % October 1, 2025 4,943 4,943 1,668 Term Loan 13.25 % Prime 5.75 % 9.00 % - 4.00 % December 31, 2025 2,500 2,467 832 BrightInsight, Inc. (2)(12) Software Term Loan 12.50 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,619 6,619 Term Loan 12.50 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,448 3,448 Term Loan 12.50 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,448 3,448 Total Non-Affiliate Debt Investments — Healthcare information and services 30,729 25,819 Total Non- Affiliate Debt Investments 701,074 686,458 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 9.4% Non-Affiliate Warrants — Life Science — 3.1% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,442 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 335 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 53 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 263 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 463,915 126 125 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 21,120 35 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 47,452 366 — Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,502 66 — IMV Inc. (2)(5)(12) Biotechnology Common Stock Warrant 39,774 67 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,077 51 60 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 252,161 146 — Native Microbials, Inc (2) (12) Biotechnology Preferred Stock Warrant 103,679 64 162 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 3,024 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 203,017 399 648 Rocket Pharmaceuticals Corporation (5)(12) Biotechnology Common Stock Warrant 7,051 17 14 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 37 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 3 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 64 1,200 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 48 31 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 84 1,864 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 209 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 775,000 148 179 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 226 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 153 150 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 394 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 113 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 385 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 101 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 16 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 19,662 40 46 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 605,313 98 123 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 83 Total Non-Affiliate Warrants — Life Science 4,197 9,792 Non-Affiliate Warrants — Sustainability — 0.6% Aerofarms, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 201,537 61 74 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,539 39 55 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Common Stock Warrant 204,832 488 1,061 Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 361 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 35,906 126 268 Total Non-Affiliate Warrants — Sustainability 928 1,819 Non-Affiliate Warrants — Technology — 5.1% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 67 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 139 3,265 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 173 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 64 Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 10,690 26 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,069 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 17,605 20 61 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 30 125 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 31,966 56 233 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,947 2,947 Interior Define, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,710 103 — MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 143 29 37 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 1,261,253 197 17 Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,600 104 104 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 429 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 534 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 22 Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 42 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 909 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 442,110 234 407 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 — Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 357 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 802 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 243 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,610 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrants 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 69 Decisyon, Inc. (12) Software Common Stock Warrant 82,967 46 — Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 197 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 3 Groundspeed Analytics, Inc. (2)(12) Software Preferred Stock Warrant 86,300 6 6 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 296 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 34 41 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 288,115 22 312 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 80,197 40 44 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 39 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 46 99 Riv Data Corp. (2)(12) Software Preferred Stock Warrant 321,428 12 296 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Skyword, Inc. (12) Software Preferred and Common Stock Warrants 301,055 48 1 Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 133 Supply Network Visiblity Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 83 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,249 16,148 See Notes to Consolidated Financial Statements Horizon Technology Finance Corporation and Subsidiaries Consolidated Schedule of Investments December 31, 2022 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 159,893 47 54 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,370 Secure Transfusion Services, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 77,690 47 — BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 80,544 160 170 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 60 359 Total Non-Affiliate Warrants — Healthcare information and services 416 1,953 Total Non-Affiliate Warrants 14,790 29,712 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (2) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 0.8% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (2)(12) Biotechnology Common Stock 32,831 356 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 57 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 8 83 Lumithera, Inc. (2) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (2) Other Sustainability Preferred 22,313 8 27 Branded Online, Inc. (2)(5) Software Common Stock 108,004 1,079 83 Decisyon, Inc. (12) Software Preferred and Common Stock 72,638,663 230 — Total Non-Affiliate Equity 4,184 2,556 Total Non-Affiliate Portfolio Investment Assets $ 721,248 $ 720,026 Total Portfolio Investment Assets — 226.1% $ 721,248 $ 720,026 Short Term Investments — Unrestricted Investments — 2.2% US Bank Money Market Deposit Account $ 7,066 $ 7,066 Total Short Term Investments — Unrestricted Investments $ 7,066 $ 7,066 Short Term Investments — Restricted Investments — 0.9% US Bank Money Market Deposit Account $ 2,788 $ 2,788 Total Short Term Investments — Restricted Investments $ 2,788 $ 2,788 ( 1 All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States. ( 2 Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”) with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 ( “2019 November 9, 2022 ( “2022 ( 3 All non-affiliate investments are investments in which the Company owns less than 5% 5% not 25% 25% ( 4 All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not one December 31, 2022 ( 5 Portfolio company is a public company. ( 6 For debt investments, represents principal balance less unearned income. ( 7 Warrants, Equity and Other Investments are non-income producing. ( 8 Value as a percent of net assets. ( 9 As of December 31, 2022 1940 may not 70% ( 10 ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may not ( 11 Debt investment has a payment-in-kind (“PIK”) feature. ( 12 The fair value of the investment was valued using si

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Organization Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 1940 1986, not On October 28, 2010, Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, not The Company formed Horizon Funding 2019‑1 “2019‑1 May 2, 2019 2019‑1 May 15, 2019 “2019‑1 2019‑1 “2019‑1 2019‑1 2019‑1 2019 The Company and Arena Sunset SPV, LLC ("Arena") formed Horizon Funding I, LLC (“HFI”) as a Delaware limited liability company on May 9, 2018, not On April 21, 2020, April 21, 2020, The Company formed Horizon Funding 2022‑1 “2022‑1 September 30, 2022 2022‑1 October 18, 2022 ( “2022‑1 2022‑1 “2022‑1 2022‑1 2022‑1 2022 The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company. The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 2. Basis of presentation and significant accounting policies The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑K 6 10 X X” 1933, Principles of consolidation As required under GAAP and Regulation S- X, 25% April 21, 2020, not 1940 not April 21, 2020. Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may December 31, 2022 three December 31, 2021 one December 31, 2022 not December 31, 2021 two December 31, 2020 one The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not December 31, 2022, 2021 2020 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Prior to consolidating the investment in HSLFI on and after April 21, 2020, not January 1, 2020 April 21, 2020, Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of December 31, 2022 2021 December 31, 2022 2021 December 31, 2022, 2021 2020 Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no December 31, 2022, 2021 2020 Depending on the level of taxable income earned in a tax year, the Company may December 31, 2022, 2021 2020 The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not December 31, 2022 2021 2021, 2020 2019 Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may Stockholders Equity On August 2, 2019, “2019 2019 may On July 30, 2020, “2020 2020 may On August 2, 2021, 2020 “2021 2019 2020 no 2021 may may 415 On March 14, 2022 , During the year ended December 31, 2022 2021 December 31, 2021 2021 2020 December 31, 2020 2019 2020 The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of December 31, 2022 Stock Repurchase Program On April 29, 2022, may, not 10b‑18 1934, 1940 June 30, 2023 $5.0 December 31, 2022, 2021 2020 not December 31, 2022 Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not Recently adopted accounting pronouncement In March 2020, No. 2020 04, 848 2020 04” 2020 04 2020 04 March 12, 2020 December 31, 2022. December 31, 2022 2020 04, not Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 3. Related party transactions Investment Management Agreement At a special meeting of the stockholders on October 30, 2018, March 7, 2019. October 28, 2010 July 1, 2014. October 28, 2022, The Advisor’s services under the Investment Management Agreement are not not two The base management fee was and will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 $250 The base management fee payable at December 31, 2022 2021 December 31, 2022, 2021 2020 The incentive fee has two The first zero not no 1.75%, 2.1875% 20.00% not Pre-Incentive Fee Net Investment Income does not may 2.00% three The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three 11 may 20.00% zero not three The second 20.00% not The net performance based incentive fee expense was $7.7 million, $7.1 million and $5.2 million for the years ended December 31, 2022, 2021 2020 December 31, 2022, may three not December 31, 2021 2020. December 31, 2022 2021 December 31, 2022 2021 one Administration Agreement The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $1.7 million, $1.3 million and $1.0 million for years ended December 31, 2022, 2021 2020

Note 4 - Investments

Note 4 - Investments	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Investment Holdings [Text Block]	Note 4. Investments The following table shows the Company’s investments as of December 31, 2022 2021 December 31, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 701,074 $ 686,458 $ 441,885 $ 437,317 Warrants 14,790 29,712 10,023 20,200 Other 1,200 1,300 1,450 200 Equity 4,184 2,556 479 358 Total investments $ 721,248 $ 720,026 $ 453,837 $ 458,075 The following table shows the Company’s investments by industry sector as of December 31, 2022 2021 December 31, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 193,372 $ 195,006 $ 109,899 $ 107,902 Medical Device 132,803 135,960 88,681 84,567 Technology Communications 22,892 26,176 22,853 25,920 Consumer-Related 121,961 114,050 92,158 93,194 Data Storage 476 1,316 476 1,047 Internet and Media 329 1,159 569 3,305 Networking 11,831 11,710 17,390 17,964 Power Management 1,585 2,610 1,585 2,609 Semiconductors 56 — 101 — Software 120,157 118,716 60,902 60,807 Sustainability Energy Efficiency 8 27 — — Other Sustainability 84,633 85,524 46,595 47,011 Healthcare Information and Services Diagnostics 9,851 9,858 12,393 12,377 Other 7,559 3,870 175 1,177 Software 13,735 14,044 60 195 Total investments $ 721,248 $ 720,026 $ 453,837 $ 458,075 Horizon Secured Loan Fund I LLC On June 1, 2018, not April 21, 2020, April 21, 2020, During the period January 1, 2020 April 21, 2020, HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, No. 1 June 19, 2019 ( No. 1” June 1, 2018 ( June 5, 2020, three The following tables show certain summarized financial information for HSLFI for the period January 1, 2020 April 21, 2020: For the period January 1, 2020 through April 21, 2020 (In thousands) Selected Statements of Operations Information Interest income on investments $ 1,353 Total investment income $ 1,465 Total expenses $ 1,229 Net investment income $ 236 Net realized gain on investments $ 120 Net unrealized depreciation on investments $ (392 ) Net decrease in net assets resulting from operations $ (36 )

Note 5 - Transactions With Affi

Note 5 - Transactions With Affiliated Companies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	Note 5. Transactions with affiliated companies A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% not 25% For the year ended December 31, 2022, no Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2021 Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized December 31, Interest Company 2020 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2021 income (In thousands) Decisyon, Inc. (1) $ 1,181 $ — $ — $ (1,181 ) $ — $ — $ — $ — $ 41 626 — — (638 ) 12 — — — 21 227 — — (227 ) — — — — 7 228 — — (228 ) — — — — 7 685 — — (685 ) — — — — 22 276 — — (276 ) — — — — 9 183 — — (183 ) — — — — 6 120 — — (120 ) — — — — — MVI (ABC) LLC fka StereoVision, Inc. 2,382 — (2,783 ) — — — 401 — 139 — 250 (250 ) — — — — — — — 70 (70 ) — — — — — — — 330 (330 ) — — — — — — 150 (150 ) — — — — — — 1,639 — — — — (848 ) (791 ) — — Total non-controlled affiliates $ 7,547 $ 800 $ (3,583 ) $ (3,538 ) $ 12 $ (848 ) $ (390 ) $ — $ 252 ( 1 As of December 31, 2021 no 5% A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% December 31, 2022 Year ended December 31, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized December 31, Dividend Company 2021 Purchases Sales fair value declared gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ — Transactions related to investments in controlled affiliated companies for the year ended December 31, 2021 Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized December 31, Dividend Company 2020 Purchases Sales fair value declared gain/(loss) gain/(loss) 2021 income (In thousands) HESP LLC 1,500 — (50 ) — — (1,450 ) — — — Total controlled affiliates $ 1,500 $ — $ (50 ) $ — $ — $ (1,450 ) $ — $ — $ —

Note 6 - Fair Value

Note 6 - Fair Value	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 6. Fair value Prior to July 30, 2022, 2a 5 1940 July 29, 2022, twelve The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no not may not Fair value measurements focus on exit prices in an orderly transaction (that is, not may The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement three Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Observable inputs other than Level 1 not Level 3 Unobservable inputs that are supported by little or no 3 Due to the inherent uncertainty of determining the fair value of investments that do not may may may may Cash and interest receivable: not 1 Money market funds: 2 Debt investments: 3 Under certain circumstances, the Company may Warrant investments: ● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. ● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven ● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. ● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. ● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may Under certain circumstances the Company may may The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 3 Equity investments: third may 3 1 Other investments: 3 The following tables provide a summary of quantitative information about the Company’s Level 3 December 31, 2022 2021 may The following table is not 3 December 31, 2022 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 The following table is not 3 December 31, 2021 December 31, 2021 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average (1) (Dollars in thousands, except per share data) Debt investments $ 430,417 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 23% 12 % 6,900 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 50% 33 % Warrant investments 19,837 Black-Scholes Valuation Model Price Per Share 0.000 –980.0000 $ 20.35 Average Industry Volatility 25% 25 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 4 2 Other investments 200 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 0% – 100% 100 % Equity investments 203 Last Equity Financing Price Per Share 0.000 –1.0000 $ 0.41 Total Level 3 investments $ 457,557 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 Borrowings: 2 2026 7 December 31, 2022 2026 1 2027 7 December 31, 2022 2027 1 December 31, 2022 2019 7 3 December 31, 2022 2022 7 3 not Off-balance-sheet instruments: 3 The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of December 31, 2022 2021 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,066 $ — $ 7,066 Restricted investments in money market funds $ — $ 2,788 $ — $ 2,788 Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,868 $ — $ 7,868 Restricted investments in money market funds $ — $ 1,359 $ — $ 1,359 Debt investments $ — $ — $ 437,317 $ 437,317 Warrant investments — 363 19,837 20,200 Other investments — — 200 200 Equity investments 155 — 203 358 Total investments $ 155 $ 363 $ 457,557 $ 458,075 The following table shows a reconciliation of the beginning and ending balances for Level 3 December 31, 2022 Year ended December 31, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 421,372 — 606 — 421,978 Warrants and equity received and classified as Level 3 — 5,664 8 — 5,672 Principal payments received on investments (95,558 ) — — (313 ) (95,871 ) Proceeds from sale of investments (49,371 ) (464 ) — — (49,835 ) Net realized (loss) gain on investments (8,221 ) 264 — (1,137 ) (9,094 ) Unrealized (depreciation) appreciation included in earnings (10,044 ) 2,215 (401 ) 1,350 (6,880 ) Transfer out of Level 3 — (1,371 ) — (1,371 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (5,837 ) — — — (5,837 ) Level 3 assets, end of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 During the year ended December 31, 2022 three 3. 3 one 2 3 two 1 December 31, 2022 one 3. one 3 The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 December 31, 2022 The following table shows a reconciliation of the beginning and ending balances for Level 3 December 31, 2021 Year ended December 31, 2021 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 333,495 $ 12,736 $ 2,117 $ 1,700 $ 350,048 Purchase of investments 344,445 — — — 344,445 Warrants and equity received and classified as Level 3 — 2,681 — — 2,681 Principal payments received on investments (188,010 ) — — — (188,010 ) Proceeds from sale of investments (47,436 ) (3,241 ) — (13 ) (50,690 ) Net realized (loss) gain on investments (5,033 ) 2,514 — — (2,519 ) Unrealized appreciation (depreciation) included in earnings 1,836 5,218 (1,682 ) (1,487 ) 3,885 Transfer out of Level 3 — (71 ) (232 ) — (303 ) Other (1,980 ) — — — (1,980 ) Level 3 assets, end of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 During the year ended December 31, 2021 three 3. 3 one 2 3 one 1 3 one 1 The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 December 31, 2021 The Company discloses fair value information about financial instruments, whether or not not The fair value amounts have been measured as of the reporting date and have not may As of December 31, 2022 2021 Market risk The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may

Note 7 - Borrowings

Note 7 - Borrowings	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7. Borrowings The following table shows the Company’s borrowings as of December 31, 2022 2021 December 31, 2022 December 31, 2021 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 125,000 $ 5,000 $ 120,000 $ 125,000 $ 53,500 $ 71,500 NYL Facility 200,000 176,750 23,250 100,000 78,750 21,250 2019 Asset-Backed Notes 42,573 42,573 — 70,500 70,500 — 2022 Asset-Backed Notes 100,000 100,000 — — — — 2027 Notes 57,500 57,500 — — — — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 582,573 439,323 143,250 353,000 260,250 92,750 Unamortized debt issuance costs attributable to term borrowings — (5,245 ) — — (2,637 ) — Total borrowings outstanding, net $ 582,573 $ 434,078 $ 143,250 $ 353,000 $ 257,613 $ 92,750 As of December 31, 2022 1940 December 31, 2022 Credit Facilities Key Facility The Company entered into the Key Facility with Key effective November 4, 2013. June 22, 2021, may June 22, 2024. June 22, 2026. June 21, 2021, one June 30, 2021, December 31, 2022 December 31, 2021, December 31, 2022 2021 December 31, 2022 2021 December 31, 2022 2021 NYL Facility On April 21, 2020, June 1, 2018, three On February 25, 2022, June 2023 June 2028. $100.0 three There were $176.8 million and $78.8 million in advances made by the NYL Noteholders as of December 31, 2022 2021, December 31, 2022 2021 December 31, 2022 December 31, 2021 December 31, 2022 December 31, 2021 Under the terms of the NYL Facility, the Company required to maintain a reserve cash balance, which may December 31, 2022 2021, Securitizations 2019 On August 13, 2019, 2019 2019 no August 13, 2019. The 2019 2019‑1 August 13, 2019, 2019 2019 July 15, 2021 September 15, 2027. As of December 31, 2022 2021 2019 Under the terms of the 2019 2019 may 2019 December 31, 2022 2021 2022 On November 9, 2022, 2022 2022 no November 9, 2022. The 2022 2022‑1 November 9, 2022, 2022 November 15, 2024 November 15, 2030. As of December 31, 2022, 2022 Under the terms of the 2022 2022 may 2022 December 31, 2022, Unsecured Notes 2022 On September 29, 2017, 2022 October 11, 2017, 30 “2022 2022 September 15, 2022 September 15, 2019 2022 March 15, June 15, September 15 December 15 2022 2022 April 24, 2021 ( 2022 2022 2022 2026 On March 30, 2021, 2026 “2026 2026 2026 March 30, 2026 may March 30, 2023 2026 4.875% March 30, June 30, September 30 December 30 2026 2026 December 31, 2022 2026 2026 2027 On June 15, 2022, 2027 July 11, 2022, 30 “2027 2027 June 15, 2027 may June 15, 2024 2027 6.25% March 30, June 30, September 30 December 30 September 30, 2022. 2027 2027 December 31, 2022 2027 2027 The following table shows information about our senior securities as of December 31, 2022 2021 2020 2019 2018 Total Amount Outstanding Involuntary Average Exclusive of Asset Liquidation Market Treasury Coverage Preference Value per Class and Year Securities(1) per Unit(2) per Unit(3) Unit(4) (In thousands, except unit data) Credit facilities 2022 $ 181,750 $ 4,169 — N/A 2021 $ 132,250 $ 3,823 — N/A 2020 $ 50,250 $ 7,965 — N/A 2019 $ 17,000 $ 19,908 — N/A 2018 $ 90,500 $ 2,896 — N/A 2027 Notes 2022 $ 57,500 $ 13,179 — $ 24.09 2026 Notes 2022 $ 57,500 $ 13,179 — $ 24.45 2021 $ 57,500 $ 8,793 — $ 25.90 2022 Notes 2022 $ — $ — — N/A 2021 $ — $ — — N/A 2020 $ 37,375 $ 10,708 — $ 24.60 2019 $ 37,375 $ 9,055 — $ 25.53 2017 $ 37,375 $ 7,014 $ 25.52 2022-1 Securitization 2022 $ 100,000 $ 7,578 — N/A 2019-1 Securitization 2022 $ 42,573 $ 17,799 — N/A 2021 $ 70,500 $ 7,171 — N/A 2020 $ 100,000 $ 4,002 — N/A 2019 $ 100,000 $ 3,384 — N/A Total senior securities 2022 $ 439,323 $ 1,725 — N/A 2021 $ 260,250 $ 1,943 — N/A 2020 $ 187,625 $ 2,133 — N/A 2019 $ 154,375 $ 2,192 — N/A 2018 $ 127,875 $ 2,050 — N/A ( 1 Total amount of senior securities outstanding at the end of the period presented. ( 2 Asset coverage per unit is the ratio of the original cost less accumulated depreciation, amortization or impairment of the Company’s total consolidated assets, less all liabilities and indebtedness not $1,000 ( 3 The amount which the holder of such class of senior security would be entitled upon the voluntary liquidation of the applicable issuer in preference to any security junior to it. The “ — ” in this column indicates that the SEC expressly does not ( 4 Not 2019‑1 2022 1 not

Note 8 - Federal Income Tax

Note 8 - Federal Income Tax	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8. Federal income tax The Company has elected to be treated as a RIC under Subchapter M of the Code and to distribute substantially all of its taxable income. Accordingly, no not The following table reconciles net increase in net assets resulting from operations to taxable income: Years Ended December 31, 2022 2021 2020 (In thousands) Net increase in net assets resulting from operations $ 21,151 $ 27,782 $ 6,364 Net unrealized depreciation (appreciation) on investments 5,552 (3,205 ) (313 ) Other book-tax differences 3,292 1,462 782 Change in capital loss carry forward 9,484 3,643 14,698 Taxable income before deductions for distributions $ 39,479 $ 29,682 $ 21,531 The tax characters of distributions paid are as follows: Years Ended December 31, 2022 2021 2020 (In thousands) Ordinary income $ 31,490 $ 25,099 $ 21,592 Total $ 31,490 $ 25,099 $ 21,592 The components of undistributed ordinary income earnings on a tax basis were as follows: As of December 31, 2022 2021 2020 (In thousands) Undistributed ordinary income $ 18,813 $ 10,825 $ 6,242 Long term capital loss carry forward (73,055 ) (63,571 ) (59,928 ) Unrealized appreciation 18,542 12,973 9,578 Unrealized depreciation (19,771 ) (8,738 ) (8,545 ) Other temporary differences 11,875 7,465 5,983 Total $ (43,596 ) $ (41,046 ) $ (46,670 ) Depending on the level of taxable income earned in a tax year, the Company may December 31, 2022 2021 December 31, 2022 2021 Capital losses in excess of capital gains earned in a tax year may December 31, 2022, 2021 2020 not For federal income tax purposes, the tax cost of investments at December 31, 2022 2021 December 31, 2022 2021 December 31, 2022 2021

Note 9 - Financial Instruments

Note 9 - Financial Instruments With Off-balance-sheet Risk	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	Note 9. Financial instruments with off-balance-sheet risk In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $190.0 million and $114.5 million as of December 31, 2022 2021 may not The following table provides the Company’s unfunded commitments by portfolio company as of December 31, 2022 December 31, 2022 Fair Value of Unfunded Principal Commitment Balance Liability (In thousands) BrightInsight, Inc. $ 21,000 $ 278 Britecore Holdings, Inc. 5,000 66 Castle Creek Biosciences 4,000 72 Divergent Technologies, Inc. 22,500 236 Engage3, LLC 8,000 40 Groundspeed Analytics, Inc. 15,000 150 Hound Labs, Inc. 7,500 88 KSQ Therapeutics, Inc. 10,000 100 Lytics, Inc. 5,000 65 Native Microbials, Inc. 7,500 72 Optoro, Inc. 15,000 38 PDS Biotechnology Corporation 10,000 158 Robin Healthcare, Inc. 10,000 100 Scientia Vascular, Inc. 10,000 110 Slingshot Aerospace, Inc. 5,000 64 Swift Health Systems Inc. 25,500 105 Temperpack Technologies, Inc. 9,000 19 Total $ 190,000 $ 1,761 The table above also provides the fair value of the Company’s unfunded commitment liability as of December 31, 2022

Note 10 - Concentrations of Cre

Note 10 - Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 10. Concentrations of credit risk The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may may The Company’s largest debt investments may five December 31, 2022 2021 No 10% December 31, 2022 2021 five December 31, 2022, 2021 2020

Note 11 - Distributions

Note 11 - Distributions	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 11. Distributions The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the years ended December 31, 2022 2021: DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ — — $ — 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 29,619 55,095 $ 679 Year Ended December 31, 2021 10/22/21 2/18/22 3/16/22 $ 0.10 $ 2,100 3,409 $ 46 10/22/21 1/19/22 2/16/22 0.10 2,096 2,680 43 10/22/21 12/17/21 1/14/22 0.10 2,031 3,417 56 10/22/21 11/18/21 12/15/21 0.05 1,013 1,197 20 7/23/21 11/18/21 12/15/21 0.10 2,027 2,395 38 7/23/21 10/19/21 11/16/21 0.10 2,010 1,907 34 7/23/21 9/17/21 10/15/21 0.10 2,008 2,068 36 4/23/21 8/18/21 9/15/21 0.10 1,996 2,041 34 4/23/21 7/20/21 8/16/21 0.10 1,983 1,937 34 4/23/21 6/17/21 7/16/21 0.10 1,964 1,888 33 2/26/21 5/18/21 6/15/21 0.10 1,964 1,671 29 2/26/21 4/20/21 5/14/21 0.10 1,937 1,794 29 2/26/21 3/18/21 4/16/21 0.10 1,938 1,653 28 $ 1.25 $ 25,067 28,057 $ 460 On February 23, 2023, Ex-Dividend Date Record Date Payment Date Distributions Declared March 16, 2023 March 17, 2023 April 14, 2023 $ 0.11 April 17, 2023 April 18, 2023 May 16, 2023 $ 0.11 May 17, 2023 May 18, 2023 June 14, 2023 $ 0.11 After paying distributions of $1.25 per share deemed paid for tax purposes in 2022 October 28, 2022 January 13, 2023, 2022 December 31, 2022 not

Note 12 - Subsequent Events

Note 12 - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. Subsequent events In January 2023, 2021 On January 24, 2023, August 18, 2022 On February 1, 2023, On February 3, 2023, On February 14, 2023, On February 20, 2023, not On February 24, 2023, On February 24, 2023, $20.0

Note 13 - Financial Highlights

Note 13 - Financial Highlights	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Investment Company, Financial Highlights [Text Block]	Note 13. Financial highlights The following table shows financial highlights for the Company: Year ended December 31, 2022 2021 2020 2019 2018 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.56 $ 11.02 $ 11.83 $ 11.64 $ 11.72 Net investment income 1.46 1.41 1.18 1.52 1.20 Realized loss (gain) (0.38 ) (0.18 ) (0.84 ) (0.31 ) 0.06 Unrealized (depreciation) appreciation on investments (0.22 ) 0.16 0.02 0.24 (0.13 ) Net increase in net assets resulting from operations 0.86 1.39 0.36 1.45 1.13 Distributions declared (1) (1.28 ) (1.25 ) (1.25 ) (1.20 ) (1.20 ) From net investment income (1.28 ) (1.25 ) (1.25 ) (1.20 ) (1.20 ) From net realized gain on investments — — — — — Return of capital — — — — — Other (2) 0.33 0.40 0.08 (0.06 ) (0.01 ) Net asset value at end of period $ 11.47 $ 11.56 $ 11.02 $ 11.83 $ 11.64 Per share market value, beginning of period $ 15.92 $ 13.24 $ 12.93 $ 11.25 $ 11.22 Per share market value, end of period $ 11.60 $ 15.92 13.24 12.93 11.25 Total return based on a market value (3) (19.3 )% 29.7 % 12.1 % 25.6 % 11.0 % Shares outstanding at end of period 27,753,373 21,217,460 19,286,356 15,563,290 11,535,129 Ratios to average net assets: Expenses without incentive value 11.5 % 10.5 % 10.0 % 10.8 % 10.4 % Incentive fees 2.6 % 3.1 % 2.6 % 3.2 % 2.4 % Net expenses 14.1 % 13.6 % 12.6 % 14.0 % 12.8 % Net investment income with incentive fees 12.1 % 12.2 % 10.4 % 12.8 % 10.3 % Ratios, without waivers, to average net assets: Expenses without incentive value (4) 11.5 % 10.5 % 10.0 % 10.8 % 10.4 % Incentive fees (4) 2.6 % 3.1 % 2.6 % 4.4 % 3.3 % Net expenses (4) 14.1 % 13.6 % 12.6 % 15.2 % 13.7 % Net investment income with incentive fees (4) 12.1 % 12.2 % 10.4 % 11.6 % 9.4 % Net assets at the end of the period $ 318,448 $ 245,335 $ 212,597 $ 184,055 $ 134,257 Average net asset value $ 299,182 $ 231,215 $ 199,302 $ 160,008 $ 134,364 Average debt per share $ 13.70 $ 11.27 $ 9.97 $ 10.05 $ 8.62 Portfolio turnover ratio 14.6 % (5) 45.4 % (5) 38.7 % (5) 82.0 % (6) 50.4 % (6) ( 1 Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may ( 2 Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. ( 3 The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. ( 4 During the years ended December 31, 2019 2018, ( 5 Calculated by dividing the lesser of purchases or the sum of ( 1 2 ( 6 Calculated by dividing net debt investment purchases by the monthly average debt investment balance.

Note 14 - Summarized Financial

Note 14 - Summarized Financial Information for HSLFI	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 14. Horizon Secured Loan Fund I Statements of Operations (Dollars in thousands) For the period January 1, 2020 through April 21 2021 Investment income Interest income $ 1,353 Prepayment fee income 112 Total investment income 1,465 Expenses Interest expense 1,165 General and administrative 64 Total expenses 1,229 Net investment income 236 Net realized and unrealized loss on investments Net realized gain on investments 120 Net realized gain on investments 120 Net unrealized depreciation on investments (392 ) Net unrealized depreciation on investments (392 ) Net realized and unrealized loss on investments (272 ) Net decrease in net assets resulting from operations $ (36 )

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation As required under GAAP and Regulation S- X, 25% April 21, 2020, not 1940 not April 21, 2020. Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not
Use of Estimates, Policy [Policy Text Block]	Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6
Segment Reporting, Policy [Policy Text Block]	Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may December 31, 2022 three December 31, 2021 one December 31, 2022 not December 31, 2021 two December 31, 2020 one The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not December 31, 2022, 2021 2020 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Prior to consolidating the investment in HSLFI on and after April 21, 2020, not January 1, 2020 April 21, 2020, Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not
Debt, Policy [Policy Text Block]	Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of December 31, 2022 2021 December 31, 2022 2021 December 31, 2022, 2021 2020
Income Tax, Policy [Policy Text Block]	Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no December 31, 2022, 2021 2020 Depending on the level of taxable income earned in a tax year, the Company may December 31, 2022, 2021 2020 The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not December 31, 2022 2021 2021, 2020 2019
Distributions [Policy Text Block]	Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may
Stockholders' Equity, Policy [Policy Text Block]	Stockholders Equity On August 2, 2019, “2019 2019 may On July 30, 2020, “2020 2020 may On August 2, 2021, 2020 “2021 2019 2020 no 2021 may may 415 On March 14, 2022 , During the year ended December 31, 2022 2021 December 31, 2021 2021 2020 December 31, 2020 2019 2020 The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of December 31, 2022
Stock Repurchase Program [Policy Text Block]	Stock Repurchase Program On April 29, 2022, may, not 10b‑18 1934, 1940 June 30, 2023 $5.0 December 31, 2022, 2021 2020 not December 31, 2022
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently adopted accounting pronouncement In March 2020, No. 2020 04, 848 2020 04” 2020 04 2020 04 March 12, 2020 December 31, 2022. December 31, 2022 2020 04, not Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03

Consolidated Schedule of Inve_2

Consolidated Schedule of Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Investment [Table Text Block]	Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,853 $ 2,777 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,823 2,750 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,411 1,374 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,891 4,891 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,962 1,962 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,963 1,963 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,923 4,923 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % May 1, 2026 5,000 4,912 4,912 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 10,000 9,872 9,872 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 15,000 14,808 14,808 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,476 2,476 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,473 2,473 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 5,000 4,857 4,857 Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,500 2,430 2,430 IMV Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,946 4,946 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,473 2,473 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,077 6,077 Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,177 6,177 Native Microbials, Inc (2) (12) Biotechnology Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,630 3,630 Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,469 2,469 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,701 9,701 Term Loan 13.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,697 3,697 Term Loan 13.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,697 3,697 Provivi, Inc. (2)(12) Biotechnology Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,597 4,597 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 4,667 4,597 4,597 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,280 2,280 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,280 2,280 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,274 2,274 Term Loan 12.67 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,333 2,274 2,274 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,914 4,914 Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,457 2,457 Aerobiotix, LLC (2)(12) Medical Device Term Loan 13.75 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,463 2,364 Term Loan 13.75 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,463 2,364 Canary Medical Inc. (2)(12) Medical Device Term Loan 12.75 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,475 2,475 Term Loan 12.75 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,489 2,489 Term Loan 12.75 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,473 2,473 Ceribell, Inc. (2)(12) Medical Device Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,973 4,973 Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,973 4,973 Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,478 2,478 Term Loan 10.50 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,478 2,478 Cognoa, Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,466 2,466 Term Loan 13.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,932 4,932 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 12.17 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,898 3,898 Term Loan 12.17 % Libor 8.00 % 9.25 % - 10.36 % July 1, 2025 3,960 3,898 3,898 Corinth Medtech, Inc. (2)(12) Medical Device Term Loan 12.25 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 Term Loan 12.25 % Prime 5.25 % 8.50 % - 20.00 % September 15, 2022 2,500 2,500 2,500 CSA Medical, Inc. (2)(12) Medical Device Term Loan 12.37 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 1,625 1,610 1,610 Term Loan 12.37 % Libor 8.20 % 10.00 % - 5.00 % January 1, 2024 108 107 107 Term Loan 12.37 % Libor 8.20 % 10.00 % - 5.00 % March 1, 2024 2,000 1,983 1,983 Embody, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 6.50 % 9.75 % - 28.00 % August 1, 2026 2,500 2,482 2,482 InfoBionic, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 3,208 3,143 3,143 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 974 974 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,939 4,939 Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,939 4,939 Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,933 4,933 Term Loan 12.00 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,933 4,933 Term Loan 12.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,913 4,913 Term Loan 12.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,913 4,913 Robin Healthcare, Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,360 3,360 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,460 3,460 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,597 3,597 Term Loan 11.75 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,706 3,706 Sonex Health, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,476 2,476 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,476 2,476 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,476 2,476 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,453 2,453 Term Loan 13.50 % Prime 6.50 % 9.75 % - 8.00 % May 1, 2026 2,500 2,455 2,455 Spineology, Inc. (2)(12) Medical Device Term Loan 14.50 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,966 4,966 Term Loan 14.50 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,481 2,481 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 12.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,349 3,349 Term Loan 12.25 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,454 3,454 Total Non-Affiliate Debt Investments — Life Science 318,172 317,568 Non-Affiliate Debt Investments — Sustainability — 26.3% Aerofarms, Inc. (2)(12) Other Sustainability Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,699 3,699 Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,699 3,699 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,371 7,371 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,371 7,371 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 7,500 7,371 7,371 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,903 4,903 Term Loan 14.50 % Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,000 4,903 4,903 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,463 2,463 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,927 4,927 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,924 4,924 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,462 2,462 Term Loan 13.00 % Prime 5.50 % 10.00 % - 2.75 % December 1, 2026 5,000 4,900 4,900 Term Loan 13.00 % Prime 5.50 % 10.00 % - 2.75 % December 1, 2026 2,500 2,450 2,450 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,697 3,697 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2025 3,750 3,717 3,717 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 7,500 7,424 7,424 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,712 3,712 Term Loan 14.25 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2025 3,750 3,712 3,712 Total Non-Affiliate Debt Investments — Sustainability 83,705 83,705 Non-Affiliate Debt Investments — Technology — 81.4% Axiom Space, Inc. (2)(12) Communications Term Loan 13.00 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,455 7,455 Term Loan 13.00 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,455 7,455 Term Loan 13.00 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,455 7,455 Convertible Note 3.00 % July 1, 2023 250 250 306 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,966 4,966 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 5,000 4,966 4,966 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % January 1, 2025 3,000 2,979 2,979 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % December 1, 2025 1,000 976 976 Term Loan 13.75 % Prime 6.75 % 10.00 % - 3.00 % February 1, 2026 1,000 977 977 Better Place Forests Co. (2)(12)(13) Consumer-related Technologies Term Loan 13.75 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,000 4,951 3,834 Term Loan 13.75 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 1,916 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,461 3,461 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,482 2,482 Term Loan 12.75 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,500 2,482 2,482 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,478 3,478 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,238 1,238 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,715 3,715 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,238 1,238 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,715 3,715 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,238 1,238 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,698 3,698 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,698 3,698 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 12.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,082 1,082 Term Loan 12.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 1,623 1,623 Term Loan 11.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 11.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Interior Define, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 3,210 3,151 — Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % January 1, 2026 2,963 2,886 — Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 10.00 % Prime 6.75 % 10.00 % - - September 1, 2027 2,500 2,588 2,279 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 5,000 4,954 4,954 Term Loan 14.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,500 2,477 2,477 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 5,000 4,943 4,715 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,000 1,981 1,890 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,477 2,363 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 3,000 2,971 2,835 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,459 2,345 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,459 2,345 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 5,000 4,914 4,688 Term Loan 12.75 % Prime 5.75 % 9.00 % - 2.00 % December 30, 2022 2,500 2,456 2,342 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,347 2,347 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,700 2,673 2,673 Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,700 2,673 2,673 Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 3,000 2,967 2,967 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 7.75 % 11.00 % - - July 1, 2025 2,500 2,473 2,473 Term Loan 15.25 % Prime 7.75 % 11.00 % - - July 1, 2025 1,250 1,236 1,236 Term Loan 15.25 % Prime 7.75 % 11.00 % - - July 1, 2025 1,250 1,236 1,236 Liqid, Inc. (2)(12) Networking Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,333 3,286 3,286 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 3,333 3,286 3,286 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,667 1,641 1,641 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,667 1,641 1,641 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,667 1,613 1,613 BriteCore Holdings, Inc. (2)(12) Software Term Loan 13.75 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,421 2,421 Term Loan 13.75 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,487 2,487 Decisyon, Inc. (12) Software Term Loan 16.93 % Prime 9.43 % 12.68 % - 50.43 % December 31, 2022 3,295 3,295 3,295 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 14.00 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,347 6,347 Term Loan 14.00 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,859 5,859 Term Loan 14.00 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,436 2,436 Engage3, LLC (2)(12) Software Term Loan 13.25 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,678 3,678 Term Loan 13.25 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,718 3,718 Groundspeed Analytics, Inc. (2)(12) Software Term Loan 13.00 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,798 4,798 Term Loan 13.00 % Prime 5.50 % 11.00 % 18.00 % 3.00 % December 1, 2026 5,000 4,948 4,948 Kodiak Robotics, Inc. (2)(12) Software Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,826 9,826 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,826 9,826 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,913 4,913 Term Loan 13.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,913 4,913 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 14.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,947 4,947 Term Loan 14.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,474 2,474 Lytics, Inc. (2)(12) Software Term Loan 13.00 % Prime 6.00 % 9.25 % - 3.00 % July 1, 2025 2,500 2,396 2,396 Term Loan 13.00 % Prime 6.00 % 12.25 % - 3.00 % December 1, 2026 1,250 1,231 1,231 Reputation Institute, Inc. (2)(12) Software Term Loan 14.25 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 5,000 4,932 4,932 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,870 4,870 Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,933 4,933 Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,933 4,933 Term Loan 13.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,933 4,933 Supply Network Visiblity Holdings LLC (2)(12) Software Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,472 3,472 Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % February 1, 2025 3,500 3,472 3,472 Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,472 2,472 Term Loan 13.50 % Prime 6.50 % 9.75 % - 4.00 % December 1, 2025 2,500 2,472 2,472 Total Non-Affiliate Debt Investments — Technology 268,468 259,366 Non-Affiliate Debt Investments — Healthcare information and services — 8.1% Hound Labs inc. (2) (12) Diagnostics Term Loan 13.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,385 2,385 Term Loan 13.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,473 2,473 Term Loan 13.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,946 4,946 Secure Transfusion Services, Inc. (2)(12)(13) Other Healthcare Term Loan 13.25 % Prime 5.75 % 9.00 % - 4.00 % October 1, 2025 4,943 4,943 1,668 Term Loan 13.25 % Prime 5.75 % 9.00 % - 4.00 % December 31, 2025 2,500 2,467 832 BrightInsight, Inc. (2)(12) Software Term Loan 12.50 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,619 6,619 Term Loan 12.50 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,448 3,448 Term Loan 12.50 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,448 3,448 Total Non-Affiliate Debt Investments — Healthcare information and services 30,729 25,819 Total Non- Affiliate Debt Investments 701,074 686,458 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 9.4% Non-Affiliate Warrants — Life Science — 3.1% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,442 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 335 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 53 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 263 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 463,915 126 125 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 21,120 35 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 47,452 366 — Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,502 66 — IMV Inc. (2)(5)(12) Biotechnology Common Stock Warrant 39,774 67 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,077 51 60 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 252,161 146 — Native Microbials, Inc (2) (12) Biotechnology Preferred Stock Warrant 103,679 64 162 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 3,024 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 203,017 399 648 Rocket Pharmaceuticals Corporation (5)(12) Biotechnology Common Stock Warrant 7,051 17 14 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 37 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 3 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 64 1,200 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 48 31 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 84 1,864 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 209 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 775,000 148 179 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 226 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 153 150 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 394 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 113 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 385 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 101 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 16 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 19,662 40 46 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 605,313 98 123 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 83 Total Non-Affiliate Warrants — Life Science 4,197 9,792 Non-Affiliate Warrants — Sustainability — 0.6% Aerofarms, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 201,537 61 74 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,539 39 55 Nexii Building Solutions, Inc. (2)(12) Other Sustainability Common Stock Warrant 204,832 488 1,061 Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 361 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 35,906 126 268 Total Non-Affiliate Warrants — Sustainability 928 1,819 Non-Affiliate Warrants — Technology — 5.1% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 67 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 139 3,265 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 173 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 64 Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 10,690 26 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,069 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 17,605 20 61 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 30 125 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 31,966 56 233 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,947 2,947 Interior Define, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,710 103 — MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 143 29 37 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 1,261,253 197 17 Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,600 104 104 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 429 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 534 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 22 Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 42 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 909 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 442,110 234 407 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 — Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 357 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 802 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 243 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,610 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrants 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 69 Decisyon, Inc. (12) Software Common Stock Warrant 82,967 46 — Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 197 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 3 Groundspeed Analytics, Inc. (2)(12) Software Preferred Stock Warrant 86,300 6 6 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 296 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 34 41 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 288,115 22 312 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 80,197 40 44 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 39 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 46 99 Riv Data Corp. (2)(12) Software Preferred Stock Warrant 321,428 12 296 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Skyword, Inc. (12) Software Preferred and Common Stock Warrants 301,055 48 1 Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 133 Supply Network Visiblity Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 83 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,249 16,148 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 159,893 47 54 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,370 Secure Transfusion Services, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 77,690 47 — BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 80,544 160 170 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 60 359 Total Non-Affiliate Warrants — Healthcare information and services 416 1,953 Total Non-Affiliate Warrants 14,790 29,712 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (2) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 0.8% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (2)(12) Biotechnology Common Stock 32,831 356 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 57 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 8 83 Lumithera, Inc. (2) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (2) Other Sustainability Preferred 22,313 8 27 Branded Online, Inc. (2)(5) Software Common Stock 108,004 1,079 83 Decisyon, Inc. (12) Software Preferred and Common Stock 72,638,663 230 — Total Non-Affiliate Equity 4,184 2,556 Total Non-Affiliate Portfolio Investment Assets $ 721,248 $ 720,026 Total Portfolio Investment Assets — 226.1% $ 721,248 $ 720,026 Short Term Investments — Unrestricted Investments — 2.2% US Bank Money Market Deposit Account $ 7,066 $ 7,066 Total Short Term Investments — Unrestricted Investments $ 7,066 $ 7,066 Short Term Investments — Restricted Investments — 0.9% US Bank Money Market Deposit Account $ 2,788 $ 2,788 Total Short Term Investments — Restricted Investments $ 2,788 $ 2,788 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 186.7% Non-Affiliate Debt Investments — 178.3% Non-Affiliate Debt Investments — Life Science — 77.3% Castle Creek Pharmaceuticals Holdings, Inc. (2)(12) Biotechnology Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 $ 5,000 $ 4,957 $ 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Term Loan 9.30 % Libor 7.50 % 9.30 % - 5.00 % March 1, 2024 5,000 4,957 4,957 Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 5,000 4,909 4,909 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 5,000 4,909 4,909 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,500 2,454 2,454 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 5,000 4,906 4,906 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 5,000 4,906 4,906 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 2,500 2,451 2,451 Term Loan 9.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 2,500 2,451 2,451 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,500 2,420 2,420 Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 2,500 2,472 2,472 Term Loan 9.75 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,896 4,896 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,465 2,465 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,463 2,463 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 5,000 4,850 4,850 Term Loan 9.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,475 2,475 IMV Inc. (2)(5)(12) Biotechnology Term Loan 9.00 % Prime 6.25 % 9.00 % - 5.00 % July 1, 2025 5,000 4,799 4,799 Term Loan 9.00 % Prime 6.25 % 9.00 % - 5.00 % July 1, 2025 2,500 2,462 2,462 LogicBio, Inc. (2)(5)(12) Biotechnology Term Loan 8.75 % Libor 6.25 % 8.75 % - 4.50 % June 1, 2024 4,028 4,011 4,011 Provivi, Inc. (2)(12) Biotechnology Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 5,000 4,935 4,935 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 5,000 4,935 4,935 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,440 2,440 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,440 2,440 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,430 2,430 Term Loan 9.50 % Libor 8.50 % 9.50 % - 5.50 % December 1, 2024 2,500 2,430 2,430 Stealth Biotherapeutics Inc. (2)(5)(12) Biotechnology Term Loan 8.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 5,000 4,631 4,631 Term Loan 8.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,500 2,441 2,441 Canary Medical Inc. (2)(12) Medical Device Term Loan 9.00 % Prime 5.75 % 9.00 % - 7.00 % November 1, 2024 2,500 2,394 2,394 Ceribell, Inc. (2)(12) Medical Device Term Loan 8.25 % Libor 6.70 % 8.25 % - 5.50 % October 1, 2024 5,000 4,926 4,926 Term Loan 8.25 % Libor 6.70 % 8.25 % - 5.50 % October 1,

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Investment Holdings, Schedule of Investments [Table Text Block]	December 31, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 701,074 $ 686,458 $ 441,885 $ 437,317 Warrants 14,790 29,712 10,023 20,200 Other 1,200 1,300 1,450 200 Equity 4,184 2,556 479 358 Total investments $ 721,248 $ 720,026 $ 453,837 $ 458,075 December 31, 2022 December 31, 2021 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 193,372 $ 195,006 $ 109,899 $ 107,902 Medical Device 132,803 135,960 88,681 84,567 Technology Communications 22,892 26,176 22,853 25,920 Consumer-Related 121,961 114,050 92,158 93,194 Data Storage 476 1,316 476 1,047 Internet and Media 329 1,159 569 3,305 Networking 11,831 11,710 17,390 17,964 Power Management 1,585 2,610 1,585 2,609 Semiconductors 56 — 101 — Software 120,157 118,716 60,902 60,807 Sustainability Energy Efficiency 8 27 — — Other Sustainability 84,633 85,524 46,595 47,011 Healthcare Information and Services Diagnostics 9,851 9,858 12,393 12,377 Other 7,559 3,870 175 1,177 Software 13,735 14,044 60 195 Total investments $ 721,248 $ 720,026 $ 453,837 $ 458,075
Selected Statement of Operations for Nonconsolidated Investment [Table Text Block]	For the period January 1, 2020 through April 21, 2020 (In thousands) Selected Statements of Operations Information Interest income on investments $ 1,353 Total investment income $ 1,465 Total expenses $ 1,229 Net investment income $ 236 Net realized gain on investments $ 120 Net unrealized depreciation on investments $ (392 ) Net decrease in net assets resulting from operations $ (36 )

Note 5 - Transactions With Af_2

Note 5 - Transactions With Affiliated Companies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Investments in and Advances to Affiliates [Table Text Block]	Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized December 31, Interest Company 2020 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2021 income (In thousands) Decisyon, Inc. (1) $ 1,181 $ — $ — $ (1,181 ) $ — $ — $ — $ — $ 41 626 — — (638 ) 12 — — — 21 227 — — (227 ) — — — — 7 228 — — (228 ) — — — — 7 685 — — (685 ) — — — — 22 276 — — (276 ) — — — — 9 183 — — (183 ) — — — — 6 120 — — (120 ) — — — — — MVI (ABC) LLC fka StereoVision, Inc. 2,382 — (2,783 ) — — — 401 — 139 — 250 (250 ) — — — — — — — 70 (70 ) — — — — — — — 330 (330 ) — — — — — — 150 (150 ) — — — — — — 1,639 — — — — (848 ) (791 ) — — Total non-controlled affiliates $ 7,547 $ 800 $ (3,583 ) $ (3,538 ) $ 12 $ (848 ) $ (390 ) $ — $ 252 Year ended December 31, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized December 31, Dividend Company 2021 Purchases Sales fair value declared gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ — Year ended December 31, 2021 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Dividends unrealized Net realized December 31, Dividend Company 2020 Purchases Sales fair value declared gain/(loss) gain/(loss) 2021 income (In thousands) HESP LLC 1,500 — (50 ) — — (1,450 ) — — — Total controlled affiliates $ 1,500 $ — $ (50 ) $ — $ — $ (1,450 ) $ — $ — $ —

Note 6 - Fair Value (Tables)

Note 6 - Fair Value (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 December 31, 2021 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average (1) (Dollars in thousands, except per share data) Debt investments $ 430,417 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 23% 12 % 6,900 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 50% 33 % Warrant investments 19,837 Black-Scholes Valuation Model Price Per Share 0.000 –980.0000 $ 20.35 Average Industry Volatility 25% 25 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 4 2 Other investments 200 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 0% – 100% 100 % Equity investments 203 Last Equity Financing Price Per Share 0.000 –1.0000 $ 0.41 Total Level 3 investments $ 457,557
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,066 $ — $ 7,066 Restricted investments in money market funds $ — $ 2,788 $ — $ 2,788 Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Investments in money market funds $ — $ 7,868 $ — $ 7,868 Restricted investments in money market funds $ — $ 1,359 $ — $ 1,359 Debt investments $ — $ — $ 437,317 $ 437,317 Warrant investments — 363 19,837 20,200 Other investments — — 200 200 Equity investments 155 — 203 358 Total investments $ 155 $ 363 $ 457,557 $ 458,075
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Year ended December 31, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 421,372 — 606 — 421,978 Warrants and equity received and classified as Level 3 — 5,664 8 — 5,672 Principal payments received on investments (95,558 ) — — (313 ) (95,871 ) Proceeds from sale of investments (49,371 ) (464 ) — — (49,835 ) Net realized (loss) gain on investments (8,221 ) 264 — (1,137 ) (9,094 ) Unrealized (depreciation) appreciation included in earnings (10,044 ) 2,215 (401 ) 1,350 (6,880 ) Transfer out of Level 3 — (1,371 ) — (1,371 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (5,837 ) — — — (5,837 ) Level 3 assets, end of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Year ended December 31, 2021 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 333,495 $ 12,736 $ 2,117 $ 1,700 $ 350,048 Purchase of investments 344,445 — — — 344,445 Warrants and equity received and classified as Level 3 — 2,681 — — 2,681 Principal payments received on investments (188,010 ) — — — (188,010 ) Proceeds from sale of investments (47,436 ) (3,241 ) — (13 ) (50,690 ) Net realized (loss) gain on investments (5,033 ) 2,514 — — (2,519 ) Unrealized appreciation (depreciation) included in earnings 1,836 5,218 (1,682 ) (1,487 ) 3,885 Transfer out of Level 3 — (71 ) (232 ) — (303 ) Other (1,980 ) — — — (1,980 ) Level 3 assets, end of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557

Note 7 - Borrowings (Tables)

Note 7 - Borrowings (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 2022 December 31, 2021 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 125,000 $ 5,000 $ 120,000 $ 125,000 $ 53,500 $ 71,500 NYL Facility 200,000 176,750 23,250 100,000 78,750 21,250 2019 Asset-Backed Notes 42,573 42,573 — 70,500 70,500 — 2022 Asset-Backed Notes 100,000 100,000 — — — — 2027 Notes 57,500 57,500 — — — — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 582,573 439,323 143,250 353,000 260,250 92,750 Unamortized debt issuance costs attributable to term borrowings — (5,245 ) — — (2,637 ) — Total borrowings outstanding, net $ 582,573 $ 434,078 $ 143,250 $ 353,000 $ 257,613 $ 92,750
Schedule of Long-Term Debt Instruments [Table Text Block]	Total Amount Outstanding Involuntary Average Exclusive of Asset Liquidation Market Treasury Coverage Preference Value per Class and Year Securities(1) per Unit(2) per Unit(3) Unit(4) (In thousands, except unit data) Credit facilities 2022 $ 181,750 $ 4,169 — N/A 2021 $ 132,250 $ 3,823 — N/A 2020 $ 50,250 $ 7,965 — N/A 2019 $ 17,000 $ 19,908 — N/A 2018 $ 90,500 $ 2,896 — N/A 2027 Notes 2022 $ 57,500 $ 13,179 — $ 24.09 2026 Notes 2022 $ 57,500 $ 13,179 — $ 24.45 2021 $ 57,500 $ 8,793 — $ 25.90 2022 Notes 2022 $ — $ — — N/A 2021 $ — $ — — N/A 2020 $ 37,375 $ 10,708 — $ 24.60 2019 $ 37,375 $ 9,055 — $ 25.53 2017 $ 37,375 $ 7,014 $ 25.52 2022-1 Securitization 2022 $ 100,000 $ 7,578 — N/A 2019-1 Securitization 2022 $ 42,573 $ 17,799 — N/A 2021 $ 70,500 $ 7,171 — N/A 2020 $ 100,000 $ 4,002 — N/A 2019 $ 100,000 $ 3,384 — N/A Total senior securities 2022 $ 439,323 $ 1,725 — N/A 2021 $ 260,250 $ 1,943 — N/A 2020 $ 187,625 $ 2,133 — N/A 2019 $ 154,375 $ 2,192 — N/A 2018 $ 127,875 $ 2,050 — N/A

Note 8 - Federal Income Tax (Ta

Note 8 - Federal Income Tax (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Federal Income Tax Note [Table Text Block]	Years Ended December 31, 2022 2021 2020 (In thousands) Net increase in net assets resulting from operations $ 21,151 $ 27,782 $ 6,364 Net unrealized depreciation (appreciation) on investments 5,552 (3,205 ) (313 ) Other book-tax differences 3,292 1,462 782 Change in capital loss carry forward 9,484 3,643 14,698 Taxable income before deductions for distributions $ 39,479 $ 29,682 $ 21,531
Schedule of Tax Characters of Distribution Paid [Table Text Block]	Years Ended December 31, 2022 2021 2020 (In thousands) Ordinary income $ 31,490 $ 25,099 $ 21,592 Total $ 31,490 $ 25,099 $ 21,592
Schedule of Investment Company, Distributable Earnings (Loss) [Table Text Block]	As of December 31, 2022 2021 2020 (In thousands) Undistributed ordinary income $ 18,813 $ 10,825 $ 6,242 Long term capital loss carry forward (73,055 ) (63,571 ) (59,928 ) Unrealized appreciation 18,542 12,973 9,578 Unrealized depreciation (19,771 ) (8,738 ) (8,545 ) Other temporary differences 11,875 7,465 5,983 Total $ (43,596 ) $ (41,046 ) $ (46,670 )

Note 9 - Financial Instrument_2

Note 9 - Financial Instruments With Off-balance-sheet Risk (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]	December 31, 2022 Fair Value of Unfunded Principal Commitment Balance Liability (In thousands) BrightInsight, Inc. $ 21,000 $ 278 Britecore Holdings, Inc. 5,000 66 Castle Creek Biosciences 4,000 72 Divergent Technologies, Inc. 22,500 236 Engage3, LLC 8,000 40 Groundspeed Analytics, Inc. 15,000 150 Hound Labs, Inc. 7,500 88 KSQ Therapeutics, Inc. 10,000 100 Lytics, Inc. 5,000 65 Native Microbials, Inc. 7,500 72 Optoro, Inc. 15,000 38 PDS Biotechnology Corporation 10,000 158 Robin Healthcare, Inc. 10,000 100 Scientia Vascular, Inc. 10,000 110 Slingshot Aerospace, Inc. 5,000 64 Swift Health Systems Inc. 25,500 105 Temperpack Technologies, Inc. 9,000 19 Total $ 190,000 $ 1,761

Note 11 - Distributions (Tables

Note 11 - Distributions (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Dividends Declared [Table Text Block]	DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ — — $ — 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 29,619 55,095 $ 679 Year Ended December 31, 2021 10/22/21 2/18/22 3/16/22 $ 0.10 $ 2,100 3,409 $ 46 10/22/21 1/19/22 2/16/22 0.10 2,096 2,680 43 10/22/21 12/17/21 1/14/22 0.10 2,031 3,417 56 10/22/21 11/18/21 12/15/21 0.05 1,013 1,197 20 7/23/21 11/18/21 12/15/21 0.10 2,027 2,395 38 7/23/21 10/19/21 11/16/21 0.10 2,010 1,907 34 7/23/21 9/17/21 10/15/21 0.10 2,008 2,068 36 4/23/21 8/18/21 9/15/21 0.10 1,996 2,041 34 4/23/21 7/20/21 8/16/21 0.10 1,983 1,937 34 4/23/21 6/17/21 7/16/21 0.10 1,964 1,888 33 2/26/21 5/18/21 6/15/21 0.10 1,964 1,671 29 2/26/21 4/20/21 5/14/21 0.10 1,937 1,794 29 2/26/21 3/18/21 4/16/21 0.10 1,938 1,653 28 $ 1.25 $ 25,067 28,057 $ 460 Ex-Dividend Date Record Date Payment Date Distributions Declared March 16, 2023 March 17, 2023 April 14, 2023 $ 0.11 April 17, 2023 April 18, 2023 May 16, 2023 $ 0.11 May 17, 2023 May 18, 2023 June 14, 2023 $ 0.11

Note 13 - Financial Highlights

Note 13 - Financial Highlights (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Investment Company, Financial Highlights [Table Text Block]	Year ended December 31, 2022 2021 2020 2019 2018 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.56 $ 11.02 $ 11.83 $ 11.64 $ 11.72 Net investment income 1.46 1.41 1.18 1.52 1.20 Realized loss (gain) (0.38 ) (0.18 ) (0.84 ) (0.31 ) 0.06 Unrealized (depreciation) appreciation on investments (0.22 ) 0.16 0.02 0.24 (0.13 ) Net increase in net assets resulting from operations 0.86 1.39 0.36 1.45 1.13 Distributions declared (1) (1.28 ) (1.25 ) (1.25 ) (1.20 ) (1.20 ) From net investment income (1.28 ) (1.25 ) (1.25 ) (1.20 ) (1.20 ) From net realized gain on investments — — — — — Return of capital — — — — — Other (2) 0.33 0.40 0.08 (0.06 ) (0.01 ) Net asset value at end of period $ 11.47 $ 11.56 $ 11.02 $ 11.83 $ 11.64 Per share market value, beginning of period $ 15.92 $ 13.24 $ 12.93 $ 11.25 $ 11.22 Per share market value, end of period $ 11.60 $ 15.92 13.24 12.93 11.25 Total return based on a market value (3) (19.3 )% 29.7 % 12.1 % 25.6 % 11.0 % Shares outstanding at end of period 27,753,373 21,217,460 19,286,356 15,563,290 11,535,129 Ratios to average net assets: Expenses without incentive value 11.5 % 10.5 % 10.0 % 10.8 % 10.4 % Incentive fees 2.6 % 3.1 % 2.6 % 3.2 % 2.4 % Net expenses 14.1 % 13.6 % 12.6 % 14.0 % 12.8 % Net investment income with incentive fees 12.1 % 12.2 % 10.4 % 12.8 % 10.3 % Ratios, without waivers, to average net assets: Expenses without incentive value (4) 11.5 % 10.5 % 10.0 % 10.8 % 10.4 % Incentive fees (4) 2.6 % 3.1 % 2.6 % 4.4 % 3.3 % Net expenses (4) 14.1 % 13.6 % 12.6 % 15.2 % 13.7 % Net investment income with incentive fees (4) 12.1 % 12.2 % 10.4 % 11.6 % 9.4 % Net assets at the end of the period $ 318,448 $ 245,335 $ 212,597 $ 184,055 $ 134,257 Average net asset value $ 299,182 $ 231,215 $ 199,302 $ 160,008 $ 134,364 Average debt per share $ 13.70 $ 11.27 $ 9.97 $ 10.05 $ 8.62 Portfolio turnover ratio 14.6 % (5) 45.4 % (5) 38.7 % (5) 82.0 % (6) 50.4 % (6)

Note 14 - Summarized Financia_2

Note 14 - Summarized Financial Information for HSLFI (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Equity Method Investments [Table Text Block]	For the period January 1, 2020 through April 21 2021 Investment income Interest income $ 1,353 Prepayment fee income 112 Total investment income 1,465 Expenses Interest expense 1,165 General and administrative 64 Total expenses 1,229 Net investment income 236 Net realized and unrealized loss on investments Net realized gain on investments 120 Net realized gain on investments 120 Net unrealized depreciation on investments (392 ) Net unrealized depreciation on investments (392 ) Net realized and unrealized loss on investments (272 ) Net decrease in net assets resulting from operations $ (36 )

Consolidated Schedule of Inve_3

Consolidated Schedule of Investments (Details Textual) - USD ($) $ in Thousands	Oct. 22, 2020	Dec. 31, 2022	Nov. 09, 2022	Dec. 31, 2021	Aug. 13, 2019
Debt Instrument, Face Amount		$ 582,573		$ 353,000
Percentage of Nonqualifying Assets on a Cost Basis		6.50%		5.80%
Percentage of Nonqualifying Assets on a Fair Value Basis		6.60%		5.80%
Assets of Espero [Member]
Asset Acquisition, Consideration Transferred, Total	$ 7,000
Asset-backed Notes 2019 [Member]
Debt Instrument, Face Amount					$ 160,000
Asset-backed Notes 2019 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount					$ 100,000
Asset-backed Notes 2022 [Member]
Debt Instrument, Face Amount		$ 100,000	$ 157,800	$ 0
Asset-backed Notes 2022 [Member] | Affiliated Entity [Member]
Debt Instrument, Face Amount			$ 100,000

Consolidated Schedule of Inve_4

Consolidated Schedule of Investments - Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Investments at cost	$ 721,248	$ 453,837
Investments at fair value	$ 720,026	$ 458,075
NAV %	226.10%	186.70%
Money Market Funds, Unrestricted Investment [Member]
Investments at cost	$ 7,066	$ 7,868
Investments at fair value	7,066	7,868
Unrestricted Short Term Investments [Member]
Investments at cost	7,066	7,868
Investments at fair value	$ 7,066	$ 7,868
NAV %	2.20%	3.20%
Money Market Funds, Restricted Investments [Member]
Investments at cost	$ 2,788	$ 1,359
Investments at fair value	2,788	1,359
Restricted Short Term Investments [Member]
Investments at cost	2,788	1,359
Investments at fair value	$ 2,788	$ 1,359
NAV %	0.90%	0.60%
Non-affiliate [Member]
Investments at cost	$ 721,248	$ 452,387
Investments at fair value	$ 720,026	$ 458,075
NAV %	226.10%	186.70%
Non-affiliate [Member] | Warrant [Member]
Investments at cost	$ 14,790	$ 10,023
Investments at fair value	$ 29,712	$ 20,200
NAV %	9.40%	8.20%
Non-affiliate [Member] | Debt Investments [Member]
Investments at cost	$ 701,074	$ 441,885
Investments at fair value	$ 686,458	$ 437,317
NAV %	215.50%	178.30%
Non-affiliate [Member] | Other Long-Term Investments [Member]
Investments at cost	$ 1,200	$ 0
Investments at fair value	$ 1,300	$ 200
NAV %	0.40%	0.10%
Non-affiliate [Member] | Preferred and Common Stock [Member]
Investments at cost		$ 479
Investments at fair value		$ 358
Non-affiliate [Member] | Equity Securities [Member]
Investments at cost	$ 4,184
Investments at fair value	$ 2,556
NAV %	0.80%	0.10%
Controlled Affiliate [Member]
Investments at cost		$ 1,450
Investments at fair value		$ 0
NAV %		0%
Controlled Affiliate [Member] | Other Long-Term Investments [Member]
Investments at cost		$ 1,450
Investments at fair value		$ 0
Consumer-related Technologies [Member] | Interior Define, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 2,963	$ 6,000
Investments at cost	2,886	5,775
Investments at fair value	$ 0	$ 5,775
Consumer-related Technologies [Member] | Interior Define, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Jan. 01, 2026	Jan. 01, 2026
Principal Amount	$ 3,210	$ 6,500
Investments at cost	3,151	6,397
Investments at fair value	0	6,397
Consumer-related Technologies [Member] | Interior Define, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	103	103
Investments at fair value	$ 0	$ 103
Number of Shares (in shares)	553,710	553,710
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,238
Investments at fair value	$ 1,238
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,478
Investments at fair value	3,478
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	56
Investments at fair value	$ 233
Number of Shares (in shares)	31,966
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,715
Investments at fair value	$ 3,715
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,238
Investments at fair value	$ 1,238
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,715
Investments at fair value	$ 3,715
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,238
Investments at fair value	$ 1,238
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 3,750
Investments at cost	3,698
Investments at fair value	$ 3,698
Consumer-related Technologies [Member] | Divergent Technologies, Inc. [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate	11.25%
Margin	6%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 3,750
Investments at cost	3,698
Investments at fair value	$ 3,698
Consumer-related Technologies [Member] | Lyrical Foods, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	10%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	0%	9.75%
Maturity Date	Sep. 01, 2027	Jan. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,588	2,480
Investments at fair value	$ 2,279	$ 2,480
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	9%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	2%	10.10%
Maturity Date	Dec. 30, 2022	Jan. 01, 2026
Principal Amount	$ 2,000	$ 2,000
Investments at cost	1,981	1,920
Investments at fair value	$ 1,890	$ 1,920
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	9%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	2%	10.10%
Maturity Date	Dec. 30, 2022	Jan. 01, 2026
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,943	4,935
Investments at fair value	4,715	4,935
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	197	47
Investments at fair value	$ 17	$ 47
Number of Shares (in shares)	1,261,253	310,463
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,477
Investments at fair value	$ 2,363
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 3,000
Investments at cost	2,971
Investments at fair value	$ 2,835
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,459
Investments at fair value	$ 2,345
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,459
Investments at fair value	$ 2,345
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index, Eight [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 5,000
Investments at cost	4,914
Investments at fair value	$ 4,688
Consumer-related Technologies [Member] | NextCar Holding Company, Inc [Member] | Term Loan, Prime Index, Nine [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	2%
Maturity Date	Dec. 30, 2022
Principal Amount	$ 2,500
Investments at cost	2,456
Investments at fair value	2,342
Consumer-related Technologies [Member] | Aerofarms, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	61
Investments at fair value	$ 74
Number of Shares (in shares)	201,537
Consumer-related Technologies [Member] | Primary Kids, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,700	$ 3,000
Investments at cost	2,673	2,961
Investments at fair value	$ 2,673	$ 2,961
Consumer-related Technologies [Member] | Primary Kids, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 2,700	$ 3,000
Investments at cost	2,673	2,961
Investments at fair value	2,673	2,961
Consumer-related Technologies [Member] | Primary Kids, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	57	57
Investments at fair value	$ 429	$ 51
Number of Shares (in shares)	553,778	553,778
Consumer-related Technologies [Member] | Primary Kids, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,967	2,955
Investments at fair value	$ 2,967	$ 2,955
Consumer-related Technologies [Member] | Alula Holdings, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,966	4,949
Investments at fair value	$ 4,966	$ 4,949
Consumer-related Technologies [Member] | Alula Holdings, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,966	4,935
Investments at fair value	4,966	4,935
Consumer-related Technologies [Member] | Alula Holdings, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	93	93
Investments at fair value	$ 64	$ 70
Number of Shares (in shares)	20,000	20,000
Consumer-related Technologies [Member] | Alula Holdings, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 3,000	$ 3,000
Investments at cost	2,979	2,969
Investments at fair value	$ 2,979	$ 2,969
Consumer-related Technologies [Member] | Alula Holdings, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 1,000	$ 1,000
Investments at cost	976	968
Investments at fair value	$ 976	968
Consumer-related Technologies [Member] | Alula Holdings, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.75%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Feb. 01, 2026
Principal Amount	$ 1,000
Investments at cost	977
Investments at fair value	977
Consumer-related Technologies [Member] | Aterian, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	195	195
Investments at fair value	$ 0	$ 1
Number of Shares (in shares)	76,923	76,923
Consumer-related Technologies [Member] | Quip NYC Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		11.25%
Margin		8%
Floor		11.25%
Ceiling Rate		0%
ETP		3%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 10,000
Investments at cost		9,639
Investments at fair value		9,639
Consumer-related Technologies [Member] | Quip NYC Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 325	324
Investments at fair value	$ 534	$ 503
Number of Shares (in shares)	6,191	6,191
Consumer-related Technologies [Member] | Better Place Forests Co. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	1.85%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 1,916
Consumer-related Technologies [Member] | Better Place Forests Co. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	1.85%	1.85%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,951	4,928
Investments at fair value	3,834	4,928
Consumer-related Technologies [Member] | Better Place Forests Co. [Member] | Preferred Stock Warrants [Member]
Investments at cost	26	23
Investments at fair value	$ 0	$ 23
Number of Shares (in shares)	10,690	9,353
Consumer-related Technologies [Member] | Unagi, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	15.25%	11%
Margin	7.75%	7.75%
Floor	11%	11%
Ceiling Rate	0%	0%
ETP	0%	0%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 1,250	$ 1,250
Investments at cost	1,236	1,234
Investments at fair value	$ 1,236	$ 1,234
Consumer-related Technologies [Member] | Unagi, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	15.25%	11%
Margin	7.75%	7.75%
Floor	11%	11%
Ceiling Rate	0%	0%
ETP	0%	0%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,473	2,446
Investments at fair value	2,473	2,446
Consumer-related Technologies [Member] | Unagi, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	32	25
Investments at fair value	$ 22	$ 24
Number of Shares (in shares)	171,081	134,421
Consumer-related Technologies [Member] | Unagi, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	15.25%
Margin	7.75%
Floor	11%
Ceiling Rate	0%
ETP	0%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 1,250
Investments at cost	1,236
Investments at fair value	1,236
Consumer-related Technologies [Member] | Caastle, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	68	$ 68
Investments at fair value	$ 1,069	$ 823
Number of Shares (in shares)	268,591	268,591
Consumer-related Technologies [Member] | Havenly, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.50%
Margin	5%
Floor	5%
Ceiling Rate	0%
ETP	4%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 3,000
Investments at cost	1,623
Investments at fair value	$ 1,623
Consumer-related Technologies [Member] | Havenly, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.50%
Margin	5%
Floor	5%
Ceiling Rate	0%
ETP	4%
Maturity Date	Mar. 01, 2027
Principal Amount	$ 2,000
Investments at cost	1,082
Investments at fair value	1,082
Consumer-related Technologies [Member] | Havenly, Inc. [Member] | Common Stock Warrants [Member]
Investments at cost	2,947
Investments at fair value	$ 2,947
Number of Shares (in shares)	1,312,500
Consumer-related Technologies [Member] | Havenly, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11%
Margin	3.50%
Floor	10.50%
Ceiling Rate	0%
ETP	7.78%
Maturity Date	Feb. 01, 2028
Principal Amount	$ 2,813
Investments at cost	2,813
Investments at fair value	$ 2,813
Consumer-related Technologies [Member] | Havenly, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11%
Margin	3.50%
Floor	10.50%
Ceiling Rate	0%
ETP	7.78%
Maturity Date	Feb. 01, 2028
Principal Amount	$ 2,813
Investments at cost	2,813
Investments at fair value	$ 2,813
Consumer-related Technologies [Member] | CAMP NYC, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.75%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	May 01, 2026	May 01, 2026
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,461	3,430
Investments at fair value	3,461	3,430
Consumer-related Technologies [Member] | CAMP NYC, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	20	22
Investments at fair value	$ 61	$ 22
Number of Shares (in shares)	17,605	17,605
Consumer-related Technologies [Member] | Updater, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		12%
Margin		5.75%
Floor		12%
Ceiling Rate		14%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		$ 4,961
Consumer-related Technologies [Member] | Updater, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		12%
Margin		5.75%
Floor		12%
Ceiling Rate		14%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		4,961
Consumer-related Technologies [Member] | Updater, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	$ 34	34
Investments at fair value	$ 42	$ 31
Number of Shares (in shares)	108,333	108,333
Consumer-related Technologies [Member] | Updater, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		12%
Margin		5.75%
Floor		12%
Ceiling Rate		14%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 10,000
Investments at cost		9,922
Investments at fair value		$ 9,922
Consumer-related Technologies [Member] | Clara Foods Co [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%	9%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,482	2,476
Investments at fair value	$ 2,482	$ 2,476
Consumer-related Technologies [Member] | Clara Foods Co [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	9%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,482	2,476
Investments at fair value	2,482	2,476
Consumer-related Technologies [Member] | Clara Foods Co [Member] | Preferred Stock Warrants [Member]
Investments at cost	30	30
Investments at fair value	$ 125	$ 368
Number of Shares (in shares)	46,745	46,745
Consumer-related Technologies [Member] | Getaround, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 450
Investments at fair value		$ 367
Number of Shares (in shares)		651,040
Consumer-related Technologies [Member] | SnagAJob.com, Inc [Member] | Common Stock [Member]
Investments at cost	$ 8	$ 9
Investments at fair value	$ 83	$ 83
Number of Shares (in shares)	82,974	82,974
Consumer-related Technologies [Member] | MyForest Foods Co [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,477
Investments at fair value	$ 2,477
Consumer-related Technologies [Member] | MyForest Foods Co [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,954
Investments at fair value	4,954
Consumer-related Technologies [Member] | MyForest Foods Co [Member] | Preferred Stock Warrants [Member]
Investments at cost	29
Investments at fair value	$ 37
Number of Shares (in shares)	143
Consumer-related Technologies [Member] | Optoro, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	4%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,347
Investments at fair value	2,347
Consumer-related Technologies [Member] | Optoro, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	104
Investments at fair value	$ 104
Number of Shares (in shares)	6,600
Biotechnology Sector [Member]
Investments at cost	$ 193,372	$ 109,899
Investments at fair value	$ 195,006	$ 107,902
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,823	4,909
Investments at fair value	$ 2,750	$ 4,909
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,853	4,909
Investments at fair value	2,777	4,909
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Common Stock Warrants [Member]
Investments at cost	311	311
Investments at fair value	$ 0	$ 27
Number of Shares (in shares)	26,442	317,306
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Jan. 01, 2025	Jan. 01, 2025
Principal Amount	$ 1,442	$ 2,500
Investments at cost	1,411	2,454
Investments at fair value	$ 1,374	$ 2,454
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,821	4,906
Investments at fair value	$ 2,748	$ 4,906
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 2,885	$ 5,000
Investments at cost	2,821	4,906
Investments at fair value	$ 2,748	$ 4,906
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 2,500
Investments at cost	1,408	2,451
Investments at fair value	$ 1,371	$ 2,451
Biotechnology Sector [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Seven [Member]
Cash Rate	13.75%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 1,442	$ 2,500
Investments at cost	1,408	2,451
Investments at fair value	$ 1,371	$ 2,451
Biotechnology Sector [Member] | Stealth BioTherapeutics Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%	8.75%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling Rate	0%	0%
ETP	6%	6%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,457	2,441
Investments at fair value	$ 2,457	$ 2,441
Biotechnology Sector [Member] | Stealth BioTherapeutics Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%	8.75%
Margin	5.50%	5.50%
Floor	8.75%	8.75%
Ceiling Rate	0%	0%
ETP	6%	6%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,914	4,631
Investments at fair value	4,914	4,631
Biotechnology Sector [Member] | Stealth BioTherapeutics Inc. [Member] | Common Stock Warrants [Member]
Investments at cost	264	264
Investments at fair value	$ 37	$ 45
Number of Shares (in shares)	318,181	795,455
Biotechnology Sector [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] | Castle Creek Pharmaceuticals Holdings, Inc. [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0%
ETP		5%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		4,957
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member]
Cash Rate	12.50%
Margin	605%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.50%
Margin	605%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,978
Investments at fair value	$ 2,978
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.50%
Margin	605%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,891
Investments at fair value	4,891
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	214	142
Investments at fair value	$ 335	$ 148
Number of Shares (in shares)	7,404	2,428
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.50%
Margin	605%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12.50%
Margin	605%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.50%
Margin	605%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,978
Investments at fair value	2,978
Biotechnology Sector [Member] | Castle Creek Biosciences, Inc [Member] | Common Stock [Member]
Investments at cost	250
Investments at fair value	$ 250
Number of Shares (in shares)	1,162
Biotechnology Sector [Member] | Corvium, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 53	$ 54
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	661,956	661,956
Biotechnology Sector [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.07%	9.75%
Margin	790%	7.90%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 2,500
Investments at cost	1,962	2,420
Investments at fair value	1,962	2,420
Biotechnology Sector [Member] | Emalex Biosciences, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	176	139
Investments at fair value	$ 263	$ 162
Number of Shares (in shares)	110,402	92,002
Biotechnology Sector [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.07%	9.75%
Margin	790%	7.90%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Jun. 01, 2024	Jun. 01, 2024
Principal Amount	$ 1,979	$ 2,500
Investments at cost	1,963	2,472
Investments at fair value	$ 1,963	$ 2,472
Biotechnology Sector [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.07%	9.75%
Margin	790%	7.90%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Nov. 01, 2025	Nov. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,923	4,896
Investments at fair value	$ 4,923	$ 4,896
Biotechnology Sector [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate	12.07%
Margin	790%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,912
Investments at fair value	4,912
Biotechnology Sector [Member] | Emalex Biosciences, Inc. [Member] | Common Stock [Member]
Investments at cost	356
Investments at fair value	$ 356
Number of Shares (in shares)	32,831
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.75%
Margin	475%
Floor	11%
Ceiling Rate	0%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 15,000
Investments at cost	14,808
Investments at fair value	$ 14,808
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.75%
Margin	475%
Floor	11%
Ceiling Rate	0%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 10,000
Investments at cost	9,872
Investments at fair value	9,872
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Common Stock Warrants [Member]
Investments at cost	126
Investments at fair value	$ 125
Number of Shares (in shares)	463,915
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	11.75%
Margin	475%
Floor	11%
Ceiling Rate	0%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 6,000
Investments at cost	5,923
Investments at fair value	$ 5,923
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	11.75%
Margin	475%
Floor	11%
Ceiling Rate	0%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 6,000
Investments at cost	5,923
Investments at fair value	$ 5,923
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	11.75%
Margin	475%
Floor	11%
Ceiling Rate	0%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 4,000
Investments at cost	3,949
Investments at fair value	$ 3,949
Biotechnology Sector [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	11.75%
Margin	475%
Floor	11%
Ceiling Rate	0%
ETP	4.25%
Maturity Date	Jan. 01, 2028
Principal Amount	$ 4,000
Investments at cost	3,949
Investments at fair value	$ 3,949
Biotechnology Sector [Member] | F-Star Therapeutics, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,473	2,463
Investments at fair value	$ 2,473	$ 2,463
Biotechnology Sector [Member] | F-Star Therapeutics, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	625%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Apr. 01, 2025	Apr. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,465
Investments at fair value	2,476	2,465
Biotechnology Sector [Member] | F-Star Therapeutics, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	35	36
Investments at fair value	$ 0	$ 3
Number of Shares (in shares)	21,120	21,120
Biotechnology Sector [Member] | Imunon, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	$ 66	$ 65
Investments at fair value	$ 0	$ 1
Number of Shares (in shares)	16,502	295,053
Biotechnology Sector [Member] | Greenlight Biosciences, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	575%	6.25%
Floor	9%	9.50%
Ceiling Rate	0%	0%
ETP	3%	4%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,430	2,475
Investments at fair value	$ 2,430	$ 2,475
Biotechnology Sector [Member] | Greenlight Biosciences, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	575%	6.25%
Floor	9%	9.50%
Ceiling Rate	0%	0%
ETP	3%	4%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,857	4,850
Investments at fair value	4,857	$ 4,850
Biotechnology Sector [Member] | Greenlight Biosciences, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	366
Investments at fair value	$ 0
Number of Shares (in shares)	47,452
Biotechnology Sector [Member] | IMV Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9%
Margin	575%	6.25%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,473	2,462
Investments at fair value	$ 2,473	$ 2,462
Biotechnology Sector [Member] | IMV Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9%
Margin	575%	6.25%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,946	4,799
Investments at fair value	4,946	4,799
Biotechnology Sector [Member] | IMV Inc [Member] | Common Stock Warrants [Member]
Investments at cost	67	64
Investments at fair value	$ 0	$ 64
Number of Shares (in shares)	39,774	284,090
Biotechnology Sector [Member] | IMV Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	575%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	$ 4,947
Biotechnology Sector [Member] | IMV Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%
Margin	575%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	4,947
Biotechnology Sector [Member] | LogicBio, Inc [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate		8.75%
Margin		6.25%
Floor		8.75%
Ceiling Rate		0%
ETP		4.50%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 4,028
Investments at cost		4,011
Investments at fair value		4,011
Biotechnology Sector [Member] | LogicBio, Inc [Member] | Common Stock Warrants [Member]
Investments at cost		8
Investments at fair value		$ 0
Number of Shares (in shares)		7,843
Biotechnology Sector [Member] | Mustang Bio, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	146	$ 146
Investments at fair value	$ 0	$ 5
Number of Shares (in shares)	252,161	252,161
Biotechnology Sector [Member] | KSQ Therapeutics, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.25%
Margin	475%
Floor	8.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,177
Investments at fair value	$ 6,177
Biotechnology Sector [Member] | KSQ Therapeutics, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.25%
Margin	475%
Floor	8.50%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,077
Investments at fair value	6,077
Biotechnology Sector [Member] | KSQ Therapeutics, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	51
Investments at fair value	$ 60
Number of Shares (in shares)	48,077
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.67%	9.50%
Margin	850%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 5,000
Investments at cost	4,597	4,935
Investments at fair value	4,597	4,935
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	399	278
Investments at fair value	$ 648	$ 519
Number of Shares (in shares)	203,017	164,608
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.67%	9.50%
Margin	850%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 4,667	$ 5,000
Investments at cost	4,597	4,935
Investments at fair value	$ 4,597	$ 4,935
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.67%	9.50%
Margin	850%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,280	2,440
Investments at fair value	$ 2,280	$ 2,440
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate	12.67%	9.50%
Margin	850%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,280	2,440
Investments at fair value	$ 2,280	$ 2,440
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Five [Member]
Cash Rate	12.67%	9.50%
Margin	850%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,274	2,430
Investments at fair value	$ 2,274	$ 2,430
Biotechnology Sector [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Six [Member]
Cash Rate	12.67%	9.50%
Margin	850%	8.50%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	5.50%	5.50%
Maturity Date	Dec. 01, 2024	Dec. 01, 2024
Principal Amount	$ 2,333	$ 2,500
Investments at cost	2,274	2,430
Investments at fair value	2,274	2,430
Biotechnology Sector [Member] | Getaround, Inc [Member] | Common Stock [Member]
Investments at cost	253
Investments at fair value	$ 57
Number of Shares (in shares)	87,082
Biotechnology Sector [Member] | Rocket Pharmaceuticals Corporation [Member] | Common Stock Warrants [Member]
Investments at cost	$ 17	17
Investments at fair value	$ 14	$ 9
Number of Shares (in shares)	7,051	7,051
Biotechnology Sector [Member] | Native Microbials, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%
Margin	525%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,469
Investments at fair value	$ 2,469
Biotechnology Sector [Member] | Native Microbials, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%
Margin	525%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,630
Investments at fair value	3,630
Biotechnology Sector [Member] | Native Microbials, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	64
Investments at fair value	$ 162
Number of Shares (in shares)	103,679
Biotechnology Sector [Member] | PDS Biotechnology Corporation [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	575%
Floor	9.75%
Ceiling Rate	0%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,697
Investments at fair value	$ 3,697
Biotechnology Sector [Member] | PDS Biotechnology Corporation [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	575%
Floor	9.75%
Ceiling Rate	0%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,701
Investments at fair value	9,701
Biotechnology Sector [Member] | PDS Biotechnology Corporation [Member] | Common Stock Warrants [Member]
Investments at cost	160
Investments at fair value	$ 3,024
Number of Shares (in shares)	299,848
Biotechnology Sector [Member] | PDS Biotechnology Corporation [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	575%
Floor	9.75%
Ceiling Rate	0%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,697
Investments at fair value	3,697
Biotechnology Sector [Member] | Strongbridge U.S. Inc [Member] | Common Stock Warrants [Member]
Investments at cost		$ 72
Investments at fair value		$ 110
Number of Shares (in shares)		160,714
Biotechnology Sector [Member] | vTv Therapeutics Inc [Member] | Common Stock Warrants [Member]
Investments at cost	44	$ 44
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	95,293	95,293
Biotechnology Sector [Member] | Xeris Pharmaceuticals, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	$ 72
Investments at fair value	$ 3
Number of Shares (in shares)	126,000
Biotechnology Sector [Member] | HESP LLC [Member] | Other Long-Term Investments [Member]
Investments at cost		$ 1,450
Investments at fair value		$ 0
Biotechnology Sector [Member] | Controlled Affiliate [Member] | Other Long-Term Investments [Member]
NAV %		0%
Medical Device Sector [Member]
Investments at cost	$ 132,803	$ 88,681
Investments at fair value	$ 135,960	$ 84,567
Medical Device Sector [Member] | Swift Health Systems Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.25%
Margin	5.25%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,454
Investments at fair value	$ 3,454
Medical Device Sector [Member] | Swift Health Systems Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.25%
Margin	5.25%
Floor	9%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,349
Investments at fair value	3,349
Medical Device Sector [Member] | Swift Health Systems Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	71
Investments at fair value	$ 83
Number of Shares (in shares)	135,484
Medical Device Sector [Member] | Embody, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	28%	28%
Maturity Date	Aug. 01, 2026	Aug. 01, 2026
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,482	2,457
Investments at fair value	$ 2,482	$ 2,457
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12%	9.75%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,939	4,952
Investments at fair value	$ 4,939	$ 4,952
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12%	9.75%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,939	4,952
Investments at fair value	4,939	4,952
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	194	91
Investments at fair value	$ 385	$ 112
Number of Shares (in shares)	809,931	441,780
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12%	9.75%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,933	4,944
Investments at fair value	$ 4,933	$ 4,944
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	12%	9.75%
Margin	5%	5%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Mar. 01, 2025	Mar. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,933	4,944
Investments at fair value	$ 4,933	$ 4,944
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	12.50%
Margin	5%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Medical Device Sector [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	12.50%
Margin	5%
Floor	9.75%
Ceiling Rate	0%
ETP	4%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Medical Device Sector [Member] | InfoBionic, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 1,000	$ 1,000
Investments at cost	974	963
Investments at fair value	$ 974	$ 963
Medical Device Sector [Member] | InfoBionic, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Oct. 01, 2024	Oct. 01, 2024
Principal Amount	$ 3,208	$ 3,500
Investments at cost	3,143	3,397
Investments at fair value	3,143	3,397
Medical Device Sector [Member] | InfoBionic, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	124	124
Investments at fair value	$ 113	$ 121
Number of Shares (in shares)	317,647	317,647
Medical Device Sector [Member] | Aerobiotix, LLC [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	6%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	$ 2,364
Medical Device Sector [Member] | Aerobiotix, LLC [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0%
ETP	6%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	2,364
Medical Device Sector [Member] | Aerobiotix, LLC [Member] | Preferred Stock Warrants [Member]
Investments at cost	48
Investments at fair value	$ 31
Number of Shares (in shares)	27,330
Medical Device Sector [Member] | Meditrina, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 83	$ 83
Investments at fair value	$ 101	$ 122
Number of Shares (in shares)	233,993	221,510
Medical Device Sector [Member] | MacuLogix, Inc [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0%
ETP		6%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 7,500
Investments at cost		7,447
Investments at fair value		4,481
Medical Device Sector [Member] | MacuLogix, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost		238
Investments at fair value		$ 0
Number of Shares (in shares)		454,460
Medical Device Sector [Member] | MacuLogix, Inc [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0%
ETP		6%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 4,050
Investments at cost		4,022
Investments at fair value		$ 2,420
Medical Device Sector [Member] | Canary Medical Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	7%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,489
Investments at fair value	$ 2,489
Medical Device Sector [Member] | Canary Medical Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.75%	9%
Margin	5.75%	5.75%
Floor	9%	9%
Ceiling Rate	0%	0%
ETP	7%	7%
Maturity Date	Nov. 01, 2024	Nov. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,475	2,394
Investments at fair value	2,475	2,394
Medical Device Sector [Member] | Canary Medical Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	84	53
Investments at fair value	$ 1,864	$ 45
Number of Shares (in shares)	12,153	7,292
Medical Device Sector [Member] | Canary Medical Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.75%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	7%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Medical Device Sector [Member] | Scientia Vascular, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	11.75%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,706
Investments at fair value	$ 3,706
Medical Device Sector [Member] | Scientia Vascular, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	11.75%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0%
ETP	5%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,597
Investments at fair value	3,597
Medical Device Sector [Member] | Scientia Vascular, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	40
Investments at fair value	$ 46
Number of Shares (in shares)	19,662
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	8%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,476
Investments at fair value	$ 2,476
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	9.25%
Margin	6.50%	6%
Floor	9.75%	9.25%
Ceiling Rate	0%	0%
ETP	8%	5%
Maturity Date	Jun. 01, 2025	Jun. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,391
Investments at fair value	2,476	2,391
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	98	77
Investments at fair value	$ 123	$ 75
Number of Shares (in shares)	605,313	484,250
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate		9.25%
Margin		6%
Floor		9.25%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	9.25%
Margin	6.50%	6%
Floor	9.75%	9.25%
Ceiling Rate	0%	0%
ETP	8%	5%
Maturity Date	Jun. 01, 2025	Jun. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,476	2,472
Investments at fair value	$ 2,476	2,472
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	8%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Medical Device Sector [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.50%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	8%
Maturity Date	May 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,455
Investments at fair value	2,455
Medical Device Sector [Member] | VERO Biotech LLC [Member] | Preferred Stock Warrants [Member]
Investments at cost	53	53
Investments at fair value	$ 1	$ 30
Number of Shares (in shares)	408	408
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,973
Investments at fair value	$ 4,973
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,973
Investments at fair value	4,973
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,926
Investments at fair value		4,926
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	69	61
Investments at fair value	$ 209	$ 172
Number of Shares (in shares)	145,483	134,299
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,478
Investments at fair value	$ 2,478
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,466
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	10.50%
Margin	3.50%
Floor	8.25%
Ceiling Rate	0%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,478
Investments at fair value	2,478
Medical Device Sector [Member] | Ceribell, Inc. [Member] | Term Loan, LIBOR Index, Four [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		2,466
Medical Device Sector [Member] | Lumithera, Inc. [Member] | Royalty Agreement [Member]
Investments at cost	1,200
Investments at fair value	1,100
Medical Device Sector [Member] | Lumithera, Inc. [Member] | Common Stock [Member]
Investments at cost	2,000
Investments at fair value	$ 1,700
Number of Shares (in shares)	392,651
Medical Device Sector [Member] | ZetrOZ, Inc [Member] | Royalty Agreement [Member]
Investments at cost	$ 0	0
Investments at fair value	$ 200	$ 200
Medical Device Sector [Member] | Cognoa, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0%
ETP	6%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,932
Investments at fair value	$ 4,932
Medical Device Sector [Member] | Cognoa, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0%
ETP	6%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,466
Investments at fair value	2,466
Medical Device Sector [Member] | Cognoa, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	148
Investments at fair value	$ 179
Number of Shares (in shares)	775,000
Medical Device Sector [Member] | Spineology, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	1%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,481
Investments at fair value	$ 2,481
Medical Device Sector [Member] | Spineology, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	10.25%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling Rate	0%	0%
ETP	1%	1%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,966	4,928
Investments at fair value	$ 4,966	$ 4,928
Medical Device Sector [Member] | Conventus Orthopaedics, Inc [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.17%	9.25%
Margin	8%	8%
Floor	9.25%	9.25%
Ceiling Rate	0%	0%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 4,056
Investments at cost	3,898	4,009
Investments at fair value	3,898	4,009
Medical Device Sector [Member] | Conventus Orthopaedics, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	221	149
Investments at fair value	$ 226	$ 169
Number of Shares (in shares)	7,972,222	6,361,111
Medical Device Sector [Member] | Conventus Orthopaedics, Inc [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.17%	9.25%
Margin	8%	8%
Floor	9.25%	9.25%
Ceiling Rate	0%	0%
ETP	10.36%	10.36%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 3,960	$ 4,056
Investments at cost	3,898	4,009
Investments at fair value	$ 3,898	$ 4,009
Medical Device Sector [Member] | Corinth Medtech, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.25%	8.50%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling Rate	0%	0%
ETP	20%	20%
Maturity Date	Sep. 15, 2022	Apr. 01, 2022
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,500	2,495
Investments at fair value	$ 2,500	$ 2,495
Medical Device Sector [Member] | Corinth Medtech, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.25%	8.50%
Margin	5.25%	5.25%
Floor	8.50%	8.50%
Ceiling Rate	0%	0%
ETP	20%	20%
Maturity Date	Sep. 15, 2022	Apr. 01, 2022
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,500	2,495
Investments at fair value	2,500	2,495
Medical Device Sector [Member] | AccuVein Inc [Member] | Common Stock Warrants [Member]
Investments at cost	24	24
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	1,175	1,175
Medical Device Sector [Member] | Tigo Energy, Inc. [Member] | Preferred Stock [Member]
Investments at cost	$ 8
Investments at fair value	$ 27
Number of Shares (in shares)	22,313
Medical Device Sector [Member] | Aerin Medical, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 64	$ 66
Investments at fair value	$ 1,200	$ 463
Number of Shares (in shares)	1,818,183	1,818,183
Medical Device Sector [Member] | CSA Medical, Inc [Member] | Term Loan, LIBOR Index, One [Member]
Cash Rate	12.37%	10%
Margin	8.20%	8.20%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 1,625	$ 3,125
Investments at cost	1,610	3,095
Investments at fair value	1,610	3,095
Medical Device Sector [Member] | CSA Medical, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	153	154
Investments at fair value	$ 150	$ 108
Number of Shares (in shares)	1,375,727	1,375,727
Medical Device Sector [Member] | CSA Medical, Inc [Member] | Term Loan, LIBOR Index, Two [Member]
Cash Rate	12.37%	10%
Margin	8.20%	8.20%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Jan. 01, 2024	Jan. 01, 2024
Principal Amount	$ 108	$ 208
Investments at cost	107	206
Investments at fair value	$ 107	$ 206
Medical Device Sector [Member] | CSA Medical, Inc [Member] | Term Loan, LIBOR Index, Three [Member]
Cash Rate	12.37%	10%
Margin	8.20%	8.20%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	5%	5%
Maturity Date	Mar. 01, 2024	Mar. 01, 2024
Principal Amount	$ 2,000	$ 3,600
Investments at cost	1,983	3,569
Investments at fair value	1,983	3,569
Medical Device Sector [Member] | CVRx, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	76	80
Investments at fair value	$ 394	$ 90
Number of Shares (in shares)	47,410	47,410
Medical Device Sector [Member] | Robin Healthcare, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,500
Investments at cost	3,460
Investments at fair value	$ 3,460
Medical Device Sector [Member] | Robin Healthcare, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,500
Investments at cost	3,360
Investments at fair value	3,360
Software Sector [Member]
Investments at cost	120,157	$ 60,902
Investments at fair value	$ 118,716	$ 60,807
Software Sector [Member] | DropOff, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,000	$ 6,000
Investments at cost	5,859	5,816
Investments at fair value	$ 5,859	$ 5,816
Software Sector [Member] | DropOff, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	3.50%	3.50%
Maturity Date	Apr. 01, 2026	Apr. 01, 2026
Principal Amount	$ 6,500	$ 6,500
Investments at cost	6,347	6,087
Investments at fair value	6,347	6,087
Software Sector [Member] | DropOff, Inc. [Member] | Common Stock Warrants [Member]
Investments at cost	455	397
Investments at fair value	$ 197	$ 395
Number of Shares (in shares)	516,732	482,283
Software Sector [Member] | DropOff, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,436
Investments at fair value	$ 2,436
Software Sector [Member] | Engage3, LLC [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,718
Investments at fair value	$ 3,718
Software Sector [Member] | Engage3, LLC [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,678
Investments at fair value	3,678
Software Sector [Member] | BrightInsight, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	160
Investments at fair value	$ 170
Number of Shares (in shares)	80,544
Software Sector [Member] | Groundspeed Analytics, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%
Margin	5.50%
Floor	11%
Ceiling Rate	18%
ETP	3%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,948
Investments at fair value	$ 4,948
Software Sector [Member] | Groundspeed Analytics, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%
Margin	5.50%
Floor	11%
Ceiling Rate	18%
ETP	3%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,798
Investments at fair value	4,798
Software Sector [Member] | Groundspeed Analytics, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	6
Investments at fair value	$ 6
Number of Shares (in shares)	86,300
Software Sector [Member] | Medsphere Systems Corporation [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 60	$ 60
Investments at fair value	$ 359	$ 195
Number of Shares (in shares)	7,097,792	7,097,792
Software Sector [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,826
Investments at fair value	$ 9,826
Software Sector [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,826
Investments at fair value	9,826
Software Sector [Member] | Kodiak Robotics, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	273
Investments at fair value	$ 296
Number of Shares (in shares)	639,918
Software Sector [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Software Sector [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0%
ETP	4%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,913
Investments at fair value	$ 4,913
Software Sector [Member] | Lemongrass Holdings, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 2,474
Software Sector [Member] | Lemongrass Holdings, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	4,947
Software Sector [Member] | Lemongrass Holdings, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	34
Investments at fair value	$ 41
Number of Shares (in shares)	101,308
Software Sector [Member] | Lytics, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%
Margin	6%
Floor	12.25%
Ceiling Rate	0%
ETP	3%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 1,250
Investments at cost	1,231
Investments at fair value	$ 1,231
Software Sector [Member] | Lytics, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%	9.25%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling Rate	0%	0%
ETP	3%	4%
Maturity Date	Jul. 01, 2025	Jul. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,396	2,464
Investments at fair value	2,396	2,464
Software Sector [Member] | Lytics, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	40	12
Investments at fair value	$ 44	$ 12
Number of Shares (in shares)	80,197	26,733
Software Sector [Member] | Reputation Institute, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	10.50%
Margin	7.25%	7.25%
Floor	10.50%	10.50%
Ceiling Rate	0%	0%
ETP	3%	3%
Maturity Date	Aug. 01, 2025	Aug. 01, 2025
Principal Amount	$ 5,000	$ 5,000
Investments at cost	4,932	4,905
Investments at fair value	4,932	4,905
Software Sector [Member] | Reputation Institute, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	56	54
Investments at fair value	$ 39	$ 52
Number of Shares (in shares)	3,731	3,731
Software Sector [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,933
Investments at fair value	$ 4,933
Software Sector [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,870
Investments at fair value	4,870
Software Sector [Member] | Slingshot Aerospace, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	123
Investments at fair value	$ 133
Number of Shares (in shares)	309,208
Software Sector [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,933
Investments at fair value	$ 4,933
Software Sector [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0%
ETP	5%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,933
Investments at fair value	4,933
Software Sector [Member] | Branded Online, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		6%
Maturity Date		Nov. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,355
Investments at fair value		$ 2,355
Software Sector [Member] | Branded Online, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		6%
Maturity Date		Sep. 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,719
Investments at fair value		4,719
Software Sector [Member] | Branded Online, Inc [Member] | Common Stock Warrants [Member]
Investments at cost		370
Investments at fair value		$ 443
Number of Shares (in shares)		16,678
Software Sector [Member] | Branded Online, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		0%
Maturity Date		Jul. 01, 2023
Principal Amount		$ 5,000
Investments at cost		5,000
Investments at fair value		$ 5,000
Software Sector [Member] | Branded Online, Inc [Member] | Common Stock [Member]
Investments at cost	1,079
Investments at fair value	$ 83
Number of Shares (in shares)	108,004
Software Sector [Member] | Decisyon, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	16.93%	12.68%
Margin	9.43%	9.23%
Floor	12.68%	12.68%
Ceiling Rate	0%	0%
ETP	50.43%	50.43%
Maturity Date	Dec. 31, 2022	Jan. 01, 2023
Principal Amount	$ 3,295	$ 3,470
Investments at cost	3,295	3,470
Investments at fair value	3,295	3,470
Software Sector [Member] | Decisyon, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	46	46
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	82,967	82,967
Software Sector [Member] | Decisyon, Inc [Member] | Preferred and Common Stock [Member]
Investments at cost	$ 230	$ 230
Investments at fair value	$ 0	$ 120
Number of Shares (in shares)	72,638,663	72,638,663
Software Sector [Member] | Supply Network Visiblity Holdings LLC [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,472	3,458
Investments at fair value	$ 3,472	$ 3,458
Software Sector [Member] | Supply Network Visiblity Holdings LLC [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Feb. 01, 2025	Feb. 01, 2025
Principal Amount	$ 3,500	$ 3,500
Investments at cost	3,472	3,458
Investments at fair value	3,472	3,458
Software Sector [Member] | Supply Network Visiblity Holdings LLC [Member] | Preferred Stock Warrants [Member]
Investments at cost	64	64
Investments at fair value	$ 83	$ 62
Number of Shares (in shares)	682	682
Software Sector [Member] | Supply Network Visiblity Holdings LLC [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,472	2,463
Investments at fair value	$ 2,472	$ 2,463
Software Sector [Member] | Supply Network Visiblity Holdings LLC [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.50%	9.75%
Margin	6.50%	6.50%
Floor	9.75%	9.75%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Dec. 01, 2025	Dec. 01, 2025
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,472	2,463
Investments at fair value	$ 2,472	$ 2,463
Software Sector [Member] | Britecore Holdings, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.75%	10.50%
Margin	6.75%	7.25%
Floor	10%	10.50%
Ceiling Rate	0%	0%
ETP	5%	4%
Maturity Date	Mar. 01, 2026	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,487	2,481
Investments at fair value	$ 2,487	$ 2,481
Software Sector [Member] | Britecore Holdings, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.75%	10.50%
Margin	6.75%	7.25%
Floor	10%	10.50%
Ceiling Rate	0%	0%
ETP	5%	4%
Maturity Date	Mar. 01, 2026	Oct. 01, 2024
Principal Amount	$ 2,500	$ 2,500
Investments at cost	2,421	2,481
Investments at fair value	2,421	2,481
Software Sector [Member] | Britecore Holdings, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	21	5
Investments at fair value	$ 69	$ 37
Number of Shares (in shares)	77,828	55,591
Software Sector [Member] | E La Carte, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,958
Investments at fair value		$ 2,958
Software Sector [Member] | E La Carte, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,937
Investments at fair value		2,937
Software Sector [Member] | E La Carte, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	$ 60
Investments at fair value	$ 3
Number of Shares (in shares)	147,361
Software Sector [Member] | E La Carte, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost		61
Investments at fair value		$ 53
Number of Shares (in shares)		181,947
Software Sector [Member] | E La Carte, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0%
ETP		4%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 1,500
Investments at cost		1,479
Investments at fair value		1,479
Software Sector [Member] | Lotame Solutions, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 22	23
Investments at fair value	$ 312	$ 276
Number of Shares (in shares)	288,115	288,115
Software Sector [Member] | Revinate Holdings, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 46	$ 44
Investments at fair value	$ 99	$ 66
Number of Shares (in shares)	682,034	615,475
Software Sector [Member] | Riv Data Corp [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 12	$ 12
Investments at fair value	$ 296	$ 292
Number of Shares (in shares)	321,428	321,428
Software Sector [Member] | SIGNiX, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 225	$ 224
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	186,235	186,235
Software Sector [Member] | Skyword, Inc [Member] | Warrant [Member]
Investments at cost	$ 48	$ 49
Investments at fair value	$ 1	$ 4
Number of Shares (in shares)	301,055	301,055
Software Sector [Member] | Topia Mobility, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 138	$ 138
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	3,049,607	3,049,607
Software Sector [Member] | xAd, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 177	$ 179
Investments at fair value	$ 12	$ 1
Number of Shares (in shares)	4,343,348	4,343,348
Diagnostics Sector [Member]
Investments at cost	$ 9,851	$ 12,393
Investments at fair value	$ 9,858	$ 12,377
Diagnostics Sector [Member] | Hound Labs, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Diagnostics Sector [Member] | Hound Labs, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,385
Investments at fair value	2,385
Diagnostics Sector [Member] | Hound Labs, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost	47
Investments at fair value	$ 54
Number of Shares (in shares)	159,893
Diagnostics Sector [Member] | Hound Labs, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.50%
Margin	6%
Floor	9.25%
Ceiling Rate	0%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,946
Investments at fair value	4,946
Diagnostics Sector [Member] | IDbyDNA, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,936
Investments at fair value		$ 4,936
Diagnostics Sector [Member] | IDbyDNA, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,902
Investments at fair value		4,902
Diagnostics Sector [Member] | IDbyDNA, Inc. [Member] | Preferred Stock Warrants [Member]
Investments at cost		112
Investments at fair value		$ 95
Number of Shares (in shares)		472,006
Diagnostics Sector [Member] | IDbyDNA, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate		9%
Margin		5.75%
Floor		9%
Ceiling Rate		0%
ETP		5.50%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,444
Investments at fair value		2,444
Communications Sector [Member]
Investments at cost	22,892	22,853
Investments at fair value	$ 26,176	$ 25,920
Communications Sector [Member] | Axiom Space, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13%	9.25%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,455	7,442
Investments at fair value	$ 7,455	$ 7,442
Communications Sector [Member] | Axiom Space, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13%	9.25%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,455	7,442
Investments at fair value	7,455	7,442
Communications Sector [Member] | Axiom Space, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	46	45
Investments at fair value	$ 67	$ 42
Number of Shares (in shares)	1,991	1,991
Communications Sector [Member] | Axiom Space, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13%	9.25%
Margin	6%	6%
Floor	9.25%	9.25%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2026	Jun. 01, 2026
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,455	7,442
Investments at fair value	$ 7,455	$ 7,442
Communications Sector [Member] | Axiom Space, Inc [Member] | Convertible Note (3.00%, Due 7/1/23) [Member]
Cash Rate	3%	3%
Maturity Date	Jul. 01, 2023	Jul. 01, 2023
Principal Amount	$ 250	$ 250
Investments at cost	250	250
Investments at fair value	306	250
Communications Sector [Member] | Intelepeer Holdings, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	139	140
Investments at fair value	$ 3,265	$ 3,141
Number of Shares (in shares)	2,936,535	2,936,535
Communications Sector [Member] | PebblePost, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 173	$ 161
Number of Shares (in shares)	598,850	598,850
Life Science [Member] | Non-affiliate [Member] | Warrant [Member]
NAV %		1%
Life Science [Member] | Non-affiliate [Member] | Debt Investments [Member]
Investments at cost	$ 318,172
Investments at fair value	$ 317,568
NAV %	99.70%
Other Healthcare Sector [Member] | Kate Farms, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 102	$ 101
Investments at fair value	$ 1,370	$ 1,177
Number of Shares (in shares)	82,965	82,965
Other Healthcare Sector [Member] | Secure Transfusion Services, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	4%
Maturity Date	Dec. 31, 2025
Principal Amount	$ 2,500
Investments at cost	2,467
Investments at fair value	$ 832
Other Healthcare Sector [Member] | Secure Transfusion Services, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%
Margin	5.75%
Floor	9%
Ceiling Rate	0%
ETP	4%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 4,943
Investments at cost	4,943
Investments at fair value	1,668
Other Healthcare Sector [Member] | Secure Transfusion Services, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	47
Investments at fair value	$ 0
Number of Shares (in shares)	77,690
Other Healthcare Sector [Member] | Watermark Medical, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 74
Investments at fair value		$ 0
Number of Shares (in shares)		27,373
Other Sustainability Sector [Member]
Investments at cost	$ 84,633	$ 46,595
Investments at fair value	$ 85,524	$ 47,011
Other Sustainability Sector [Member] | Aerofarms, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,699
Investments at fair value	$ 3,699
Other Sustainability Sector [Member] | Aerofarms, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	3%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,699
Investments at fair value	3,699
Other Sustainability Sector [Member] | Dream Holdings, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	16
Investments at fair value	$ 16
Number of Shares (in shares)	86,066
Other Sustainability Sector [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.50%	10.25%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,371	7,322
Investments at fair value	$ 7,371	$ 7,322
Other Sustainability Sector [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.50%	10.25%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,371	7,322
Investments at fair value	7,371	7,322
Other Sustainability Sector [Member] | Nexii Building Solutions, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	488	356
Investments at fair value	$ 1,061	$ 331
Number of Shares (in shares)	204,832	142,405
Other Sustainability Sector [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.50%	10.25%
Margin	7%	7%
Floor	10.25%	10.25%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Sep. 01, 2025	Sep. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,371	7,322
Investments at fair value	$ 7,371	$ 7,322
Other Sustainability Sector [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.50%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,903
Investments at fair value	$ 4,903
Other Sustainability Sector [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.50%
Margin	7%
Floor	10.25%
Ceiling Rate	0%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,903
Investments at fair value	$ 4,903
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	$ 4,927
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	2,463
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	214
Investments at fair value	$ 361
Number of Shares (in shares)	681
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,924
Investments at fair value	$ 4,924
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%
Margin	6.75%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,462
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13%
Margin	5.50%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,900
Investments at fair value	$ 4,900
Other Sustainability Sector [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, Six [Member]
Cash Rate	13%
Margin	5.50%
Floor	10%
Ceiling Rate	0%
ETP	2.75%
Maturity Date	Dec. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,450
Investments at fair value	2,450
Other Sustainability Sector [Member] | LiquiGlide, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0%
ETP		5%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 2,000
Investments at cost		1,928
Investments at fair value		1,928
Other Sustainability Sector [Member] | LiquiGlide, Inc [Member] | Common Stock Warrants [Member]
Investments at cost	39	39
Investments at fair value	$ 55	$ 36
Number of Shares (in shares)	61,539	61,359
Other Sustainability Sector [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	14.25%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,717	3,703
Investments at fair value	$ 3,717	$ 3,703
Other Sustainability Sector [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	14.25%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Jun. 01, 2025	Jun. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,697	3,703
Investments at fair value	3,697	3,703
Other Sustainability Sector [Member] | Temperpack Technologies, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	126	107
Investments at fair value	$ 268	$ 552
Number of Shares (in shares)	35,906	48,756
Other Sustainability Sector [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	14.25%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 7,500	$ 7,500
Investments at cost	7,424	7,396
Investments at fair value	$ 7,424	$ 7,396
Other Sustainability Sector [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	14.25%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,712	3,698
Investments at fair value	$ 3,712	$ 3,698
Other Sustainability Sector [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	14.25%	10%
Margin	6.75%	6.75%
Floor	10%	10%
Ceiling Rate	0%	0%
ETP	2.50%	2.50%
Maturity Date	Oct. 01, 2025	Oct. 01, 2025
Principal Amount	$ 3,750	$ 3,750
Investments at cost	3,712	3,698
Investments at fair value	3,712	3,698
Healthcare Information and Services Segment [Member] | Non-affiliate [Member] | Warrant [Member]
Investments at cost	416	347
Investments at fair value	$ 1,953	$ 1,467
NAV %	0.60%	0.60%
Healthcare Information and Services Segment [Member] | Non-affiliate [Member] | Debt Investments [Member]
Investments at cost	$ 30,729	$ 12,282
Investments at fair value	$ 25,819	$ 12,282
NAV %	8.10%	5%
Life Science Segment [Member] | Non-affiliate [Member] | Warrant [Member]
Investments at cost	$ 4,197	$ 2,893
Investments at fair value	$ 9,792	2,600
NAV %	3.10%
Life Science Segment [Member] | Non-affiliate [Member] | Debt Investments [Member]
Investments at cost		194,237
Investments at fair value		$ 189,669
NAV %		77.30%
Networking Sector [Member]
Investments at cost	$ 11,831	$ 17,390
Investments at fair value	$ 11,710	$ 17,964
Networking Sector [Member] | Liqid, Inc [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 3,333	$ 5,000
Investments at cost	3,286	4,924
Investments at fair value	$ 3,286	$ 4,924
Networking Sector [Member] | Liqid, Inc [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 3,333	$ 5,000
Investments at cost	3,286	4,770
Investments at fair value	3,286	4,770
Networking Sector [Member] | Liqid, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	364	364
Investments at fair value	$ 243	$ 938
Number of Shares (in shares)	344,102	344,102
Networking Sector [Member] | Liqid, Inc [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,667	$ 2,500
Investments at cost	1,641	2,459
Investments at fair value	$ 1,641	$ 2,459
Networking Sector [Member] | Liqid, Inc [Member] | Term Loan, Prime Index, Four [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,667	$ 2,500
Investments at cost	1,641	2,459
Investments at fair value	$ 1,641	$ 2,459
Networking Sector [Member] | Liqid, Inc [Member] | Term Loan, Prime Index, Five [Member]
Cash Rate	13.25%	9.50%
Margin	6.25%	6.25%
Floor	9.50%	9.50%
Ceiling Rate	0%	0%
ETP	4%	4%
Maturity Date	Sep. 01, 2024	Sep. 01, 2024
Principal Amount	$ 1,667	$ 2,500
Investments at cost	1,613	2,414
Investments at fair value	1,613	2,414
Sustainability Segment [Member] | Non-affiliate [Member] | Warrant [Member]
Investments at cost	928	502
Investments at fair value	$ 1,819	$ 919
NAV %	0.60%	0.40%
Sustainability Segment [Member] | Non-affiliate [Member] | Debt Investments [Member]
Investments at cost	$ 83,705	$ 46,092
Investments at fair value	$ 83,705	$ 46,092
NAV %	26.30%	18.80%
Data Storage [Member] | CPG Beyond, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost		$ 242
Investments at fair value		$ 859
Number of Shares (in shares)		500,000
Data Storage [Member] | Silk, Inc [Member] | Warrant [Member]
Investments at cost		$ 234
Investments at fair value		$ 188
Number of Shares (in shares)		44,211,003
Internet and Media Sector [Member]
Investments at cost	$ 329	$ 569
Investments at fair value	1,159	3,305
Internet and Media Sector [Member] | Global Worldwide LLC [Member] | Preferred Stock Warrants [Member]
Investments at cost	75	75
Investments at fair value	$ 0	$ 6
Number of Shares (in shares)	245,810	245,810
Internet and Media Sector [Member] | Rocket Lawyer Incorporated [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 357	$ 741
Number of Shares (in shares)	261,721	261,721
Internet and Media Sector [Member] | Skillshare, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 162	$ 162
Investments at fair value	$ 802	$ 2,403
Number of Shares (in shares)	139,074	139,074
Internet and Media Sector [Member] | Zeta Global Holdings Corp [Member] | Common Stock [Member]
Investments at cost		$ 240
Investments at fair value		$ 155
Number of Shares (in shares)		18,405
Power Management Sector [Member]
Investments at cost	$ 1,585	$ 1,585
Investments at fair value	2,610	2,609
Power Management Sector [Member] | Kinestral, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost		1,585
Investments at fair value		$ 2,609
Number of Shares (in shares)		5,002,574
Power Management Sector [Member] | Halio, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	1,585
Investments at fair value	$ 2,610
Number of Shares (in shares)	5,002,574
Technology Segment [Member] | Non-affiliate [Member] | Warrant [Member]
Investments at cost	$ 9,249	$ 6,281
Investments at fair value	$ 16,148	$ 15,214
NAV %	5.10%	6.20%
Technology Segment [Member] | Non-affiliate [Member] | Debt Investments [Member]
Investments at cost	$ 268,468	$ 189,274
Investments at fair value	$ 259,366	$ 189,274
NAV %	81.40%	77.20%
Semiconductor Sector [Member]
Investments at cost	$ 56	$ 101
Investments at fair value	0	0
Semiconductor Sector [Member] | Avalanche Technology, Inc [Member] | Warrant [Member]
Investments at cost	56	101
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	6,081	6,753
Software, Healthcare Information and Service [Member]
Investments at cost	$ 13,735	$ 60
Investments at fair value	$ 14,044	195
Software, Healthcare Information and Service [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index Two [Member]
Cash Rate	12.50%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,448
Investments at fair value	$ 3,448
Software, Healthcare Information and Service [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index, One [Member]
Cash Rate	12.50%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 7,000
Investments at cost	6,619
Investments at fair value	$ 6,619
Software, Healthcare Information and Service [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index Three [Member]
Cash Rate	12.50%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0%
ETP	3%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,448
Investments at fair value	3,448
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,316	$ 1,047
Data Storage Sector [Member] | CPG Beyond, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	242
Investments at fair value	$ 909
Number of Shares (in shares)	500,000
Data Storage Sector [Member] | Silk, Inc [Member] | Preferred Stock Warrants [Member]
Investments at cost	$ 234
Investments at fair value	$ 407
Number of Shares (in shares)	442,110

Consolidated Schedule of Inve_5

Consolidated Schedule of Investments - Investments (Details) (Parentheticals)	Dec. 31, 2022	Dec. 31, 2021
NAV %	226.10%	186.70%
Non-affiliate [Member]
NAV %	226.10%	186.70%
Controlled Affiliate [Member]
NAV %		0%
Warrant [Member] | Non-affiliate [Member]
NAV %	9.40%	8.20%
Warrant [Member] | Non-affiliate [Member] | Healthcare Information and Services Segment [Member]
NAV %	0.60%	0.60%
Warrant [Member] | Non-affiliate [Member] | Life Science Segment [Member]
NAV %	3.10%
Warrant [Member] | Non-affiliate [Member] | Life Science [Member]
NAV %		1%
Warrant [Member] | Non-affiliate [Member] | Sustainability Segment [Member]
NAV %	0.60%	0.40%
Warrant [Member] | Non-affiliate [Member] | Technology Segment [Member]
NAV %	5.10%	6.20%
Other Long-Term Investments [Member] | Non-affiliate [Member]
NAV %	0.40%	0.10%
Other Long-Term Investments [Member] | Controlled Affiliate [Member] | Biotechnology Sector [Member]
NAV %		0%
Equity Securities [Member] | Non-affiliate [Member]
NAV %	0.80%	0.10%
Unrestricted Short Term Investments [Member]
NAV %	2.20%	3.20%
Restricted Short Term Investments [Member]
NAV %	0.90%	0.60%
Debt Investments [Member] | Non-affiliate [Member]
NAV %	215.50%	178.30%
Debt Investments [Member] | Non-affiliate [Member] | Healthcare Information and Services Segment [Member]
NAV %	8.10%	5%
Debt Investments [Member] | Non-affiliate [Member] | Life Science Segment [Member]
NAV %		77.30%
Debt Investments [Member] | Non-affiliate [Member] | Life Science [Member]
NAV %	99.70%
Debt Investments [Member] | Non-affiliate [Member] | Sustainability Segment [Member]
NAV %	26.30%	18.80%
Debt Investments [Member] | Non-affiliate [Member] | Technology Segment [Member]
NAV %	81.40%	77.20%

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		2 Months Ended	4 Months Ended	12 Months Ended			20 Months Ended
	Mar. 14, 2022	Mar. 03, 2022	Apr. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Apr. 23, 2022	Aug. 02, 2021	Jul. 30, 2020	Aug. 02, 2019
Investments, Nonaccrual, Interest Income				$ 0	$ 1,300	$ 30
Investment, Nonaccrual, Income Not Received in Cash, Percent				7.40%	5.90%	5.80%
Debt Issuance Costs, Net, Total		$ 7,100			$ 4,300
Deferred Finance Costs, Accumulated Amortization		4,800			3,200
Amortization of Debt Issuance Costs		1,600		$ 1,604	1,091	$ 1,018
Adjustments to Additional Paid in Capital, Non-deductible Excise Taxes Paid		$ 700			400	200
Federal Excise Tax, Percent		4%		4%			4%
Excise and Sales Taxes		$ 700		$ 715	401	222
Unrecognized Tax Benefits, Ending Balance				$ 0	0		$ 0
Open Tax Year				2019 2020 2021
Proceeds from Issuance of Common Stock				$ 84,603	$ 30,086	$ 44,611
Stock Repurchase Program, Remaining Authorized Repurchase Amount								$ 5,000
Stock Repurchased During Period, Shares (in shares)				0	0	0	167,465
Stock Repurchased During Period, Per Share (in dollars per share)							$ 11.22
Stock Repurchased During Period, Value							$ 1,900
The 2019 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value											$ 50,000
The 2020 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value										$ 100,000
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value									$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)				3,982,684
Proceeds from Issuance of Common Stock				$ 50,300
Payments of Stock Issuance Costs				1,000
Equity Sales Agreement, Remaining Amount Available for Issuance				$ 31,500			$ 31,500
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,500,000
Shares Issued, Price Per Share (in dollars per share)	$ 14.35
Proceeds from Issuance of Common Stock	$ 34,300
The 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					1,907,234
Proceeds from Issuance of Common Stock					$ 30,100
Payments of Stock Issuance Costs					800
The 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						3,702,500
Proceeds from Issuance of Common Stock						$ 44,600
Payments of Stock Issuance Costs						$ 1,000
HSLFI [Member]
Dividend Income, Operating, Total			$ 0
Three Investments [Member]
Investments, Cost, Nonaccrual Status		20,900
Investments, Fair Value, Nonaccrual Status		$ 8,300
One Investment [Member]
Investments, Cost, Nonaccrual Status					11,500
Investments, Fair Value, Nonaccrual Status					$ 6,900

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands			12 Months Ended
	Oct. 22, 2021	Oct. 30, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Management Fee Payable			$ 1,065	$ 706
Management Fee Expense			10,566	7,617	$ 6,458
Performance Based Incentive Fee			7,745	7,055	5,187
Incentive Fee Payable			1,392	2,015
Administrative Fees Expense			$ 1,667	1,285	1,016
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent		2%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million			1.60%
Management Fee Payable			$ 1,100	700
Management Fee Expense			10,600	7,600	6,500
Incentive Fee to Pre-incentive Net Investment Income	20%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Performance Based Incentive Fee			7,700	7,100	5,200
Incentive Fee Cap and Deferral Mechanism Reduction to Expense			1,000
Incentive Fee Payable			1,400	2,000
Administration Agreement [Member]
Administrative Fees Expense			$ 1,700	$ 1,300	$ 1,000

Note 4 - Investments (Details T

Note 4 - Investments (Details Textual) - USD ($) $ in Thousands		4 Months Ended	24 Months Ended	21840 Months Ended
	Apr. 21, 2020	Apr. 21, 2020	Jun. 04, 2020	Feb. 25, 2022	Jun. 19, 2019	Jun. 01, 2018
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000	$ 100,000		$ 200,000		$ 100,000
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature	$ 200,000	$ 200,000				$ 200,000
Line of Credit Facility, Advance Rate	67%	67%			67%
NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				3%
NYL Facility [Member] | USD Mid-market Wwap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	3.55%		2.75%
NYL Facility [Member] | USD Mid-market Wwap Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	5.15%		3.25%
HSLFI [Member]
Payments to Acquire Investments, Total	$ 17,100
Consideration Transferred, Percentage of Warrants Held by Investment	50%
Dividend Income, Operating, Total		$ 0

Note 4 - Investments - Investme

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments at cost	$ 721,248	$ 453,837
Investments at fair value	720,026	458,075
Biotechnology Sector [Member]
Investments at cost	193,372	109,899
Investments at fair value	195,006	107,902
Medical Device Sector [Member]
Investments at cost	132,803	88,681
Investments at fair value	135,960	84,567
Communications Sector [Member]
Investments at cost	22,892	22,853
Investments at fair value	26,176	25,920
Consumer-related Sector [Member]
Investments at cost	121,961	92,158
Investments at fair value	114,050	93,194
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,316	1,047
Internet and Media Sector [Member]
Investments at cost	329	569
Investments at fair value	1,159	3,305
Networking Sector [Member]
Investments at cost	11,831	17,390
Investments at fair value	11,710	17,964
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,610	2,609
Semiconductor Sector [Member]
Investments at cost	56	101
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	120,157	60,902
Investments at fair value	118,716	60,807
Energy Efficiency [Member]
Investments at cost	8	0
Investments at fair value	27	0
Other Sustainability Sector [Member]
Investments at cost	84,633	46,595
Investments at fair value	85,524	47,011
Diagnostics Sector [Member]
Investments at cost	9,851	12,393
Investments at fair value	9,858	12,377
Other Sector [Member]
Investments at cost	7,559	175
Investments at fair value	3,870	1,177
Software, Healthcare Information and Service [Member]
Investments at cost	13,735	60
Investments at fair value	14,044	195
Debt [Member]
Investments at cost	701,074	441,885
Investments at fair value	686,458	437,317
Warrant [Member]
Investments at cost	14,790	10,023
Investments at fair value	29,712	20,200
Other Debt Obligations [Member]
Investments at cost	1,200	1,450
Investments at fair value	1,300	200
Equity Securities [Member]
Investments at cost	4,184	479
Investments at fair value	$ 2,556	$ 358

Note 4 - Investments - Selected

Note 4 - Investments - Selected Statements of Operations (Details) - USD ($) $ in Thousands	4 Months Ended	12 Months Ended			16 Months Ended
	Apr. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 21, 2021
Interest income on investments		$ 77,366	$ 54,411	$ 42,192
Total investment income		79,191	60,015	46,035
Total expenses		42,289	31,394	25,064
Net investment income		36,187	28,220	20,749
Net realized gain on investments		(9,484)	(3,248)	(14,698)
Net unrealized appreciation on investments		(5,552)	3,205	313
Net increase in net assets resulting from operations		$ 21,151	$ 27,782	$ 6,364
HSLFI [Member]
Interest income on investments	$ 1,353				$ 1,353
Total investment income	1,465				1,465
Total expenses	1,229				1,229
Net investment income	236				236
Net realized gain on investments	120				120
Net unrealized appreciation on investments	(392)				(392)
Net increase in net assets resulting from operations	$ (36)				$ (36)

Note 5 - Transactions With Af_3

Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net unrealized (depreciation) appreciation on investments		$ (5,552)	$ 3,205	$ 313
Net realized (loss) gain on investments		(9,484)	(3,248)	(14,698)
HESP LLC [Member]
Fair value		0	1,500
Purchases		0	0
Reductions		(300)	(50)
Transfers		0	0
Net unrealized (depreciation) appreciation on investments		1,450	(1,450)
Net realized (loss) gain on investments		(1,150)	0
Fair value		0	0	1,500
Interest income		0	0
Dividends declared		0	0
Controlled Affiliate [Member]
Fair value		0	1,500
Purchases		0	0
Reductions		(300)	(50)
Transfers		0	0
Net unrealized (depreciation) appreciation on investments		1,450	(1,450)
Net realized (loss) gain on investments		(1,150)	0
Fair value		0	0	1,500
Interest income		0	0
Dividends declared		0	0
Other Affiliates [Member]
Fair value		0	7,547
Purchases			800
Reductions			(3,583)
Transfers			(3,538)
Discount accretion			12
Net unrealized (depreciation) appreciation on investments			(848)
Net realized (loss) gain on investments			(390)
Fair value			0	7,547
Interest income			252
Other Affiliates [Member] | First Decisyon Inc. Investment [Member]
Fair value	[1]	0	1,181
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(1,181)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	1,181
Interest income	[1]		41
Other Affiliates [Member] | Second Decisyon Inc. Investment [Member]
Fair value	[1]	0	626
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(638)
Discount accretion	[1]		12
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	626
Interest income	[1]		21
Other Affiliates [Member] | Third Decisyon Inc. Investment [Member]
Fair value	[1]	0	227
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(227)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	227
Interest income	[1]		7
Other Affiliates [Member] | Fourth Decisyon Inc. Investment [Member]
Fair value	[1]	0	228
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(228)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	228
Interest income	[1]		7
Other Affiliates [Member] | Fifth Decisyon Inc. Investment [Member]
Fair value	[1]	0	685
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(685)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	685
Interest income	[1]		22
Other Affiliates [Member] | Sixth Decisyon Inc. Investment [Member]
Fair value	[1]	0	276
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(276)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	276
Interest income	[1]		9
Other Affiliates [Member] | Seventh Decisyon Inc. Investment [Member]
Fair value	[1]	0	183
Purchases	[1]		0
Reductions	[1]		0
Transfers	[1]		(183)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	183
Interest income	[1]		6
Other Affiliates [Member] | Eighth Decisyon Inc. Investment [Member]
Fair value	[1]	0	120
Purchases			0
Reductions	[1]		0
Transfers	[1]		(120)
Discount accretion	[1]		0
Net unrealized (depreciation) appreciation on investments	[1]		0
Net realized (loss) gain on investments	[1]		0
Fair value	[1]		0	120
Interest income	[1]		0
Other Affiliates [Member] | First MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value		0	2,382
Purchases			0
Reductions			(2,783)
Transfers			0
Discount accretion			0
Net unrealized (depreciation) appreciation on investments			0
Net realized (loss) gain on investments			401
Fair value			0	2,382
Interest income			139
Other Affiliates [Member] | Second MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value		0	0
Purchases			250
Reductions			(250)
Transfers			0
Discount accretion			0
Net unrealized (depreciation) appreciation on investments			0
Net realized (loss) gain on investments			0
Fair value			0	0
Interest income			0
Other Affiliates [Member] | Third MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value		0	0
Purchases			70
Reductions			(70)
Transfers			0
Discount accretion			0
Net unrealized (depreciation) appreciation on investments			0
Net realized (loss) gain on investments			0
Fair value			0	0
Interest income			0
Other Affiliates [Member] | Fourth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value		0	0
Purchases			330
Reductions			(330)
Transfers			0
Discount accretion			0
Net unrealized (depreciation) appreciation on investments			0
Net realized (loss) gain on investments
Fair value			0	0
Interest income			0
Other Affiliates [Member] | Fifth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value		0	0
Purchases			150
Reductions			(150)
Transfers			0
Discount accretion			0
Net unrealized (depreciation) appreciation on investments			0
Net realized (loss) gain on investments			0
Fair value			0	0
Interest income			0
Other Affiliates [Member] | Sixth MVI (ABC) LLC fka StereoVision, Inc. Investment [Member]
Fair value		$ 0	1,639
Purchases			0
Reductions			0
Transfers			0
Discount accretion			0
Net unrealized (depreciation) appreciation on investments			(848)
Net realized (loss) gain on investments			(791)
Fair value			0	$ 1,639
Interest income			$ 0
[1]As of December 31, 2021 the Company no longer owns 5% or more of the portfolio company.

Note 6 - Fair Value (Details Te

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Unrealized Gain (Loss) on Investments	$ (5,552)	$ 3,205	$ 313
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	1,300
Fair Value, Inputs, Level 1 [Member] | Investment One [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		100
Fair Value, Inputs, Level 1 [Member] | Investment Two [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		200
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	10
Unrealized Gain (Loss) on Investments	2,600	6,300
Fair Value, Inputs, Level 3 [Member] | Debt [Member]
Unrealized Gain (Loss) on Investments	(21,000)	(5,600)
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]
Unrealized Gain (Loss) on Investments	(400)
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	$ 40	$ 100
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 23.45
The 2026 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 53,900
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) | $ / shares	$ 23.20
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 53,400
Asset-backed Notes 2019 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure, Total	42,600
Asset-backed Notes 2022 [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 100,000
Measurement Input, Hypothetical Market Yields [Member]
Debt Instrument, Measurement Input	0.25

Note 6 - Fair Value - Significa

Note 6 - Fair Value - Significant Level 3 Fair Value Measurment Inputs (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	Dec. 31, 2022 USD ($)		Dec. 31, 2021 USD ($)
Investments, fair value	$ 716,319		$ 457,557
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]
Investments, fair value	$ 669,617		$ 430,417
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	0.03		0.03
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	0.22	[1]	0.23
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]
Investments, measurement input	0.14		0.12
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value	$ 16,545		$ 6,900
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]
Investments, measurement input	0.10		0.20
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]
Investments, measurement input	0.75	[1]	0.50
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input	0.31		0.33
Debt [Member] | Convertible Note Analysis [Member]
Investments, fair value	$ 296
Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	168.93
Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	168.93
Warrant [Member] | Black-scholes Valuation Model [Member]
Investments, fair value	$ 26,145		$ 19,837
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	0.28		0.25
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	0.20		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	0		0
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]
Investments, measurement input	1		1
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	1,899	[1]	980
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]
Investments, measurement input	5	[1]	4
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	58.52		20.35
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Investments, measurement input	0.28		0.25
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	0.20		0.20
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]
Investments, measurement input	3		2
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value	$ 1,300		$ 200
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]
Investments, measurement input	1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input	0.25		0.25
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]
Investments, measurement input			0
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]
Investments, measurement input			1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]
Investments, measurement input	1		1
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]
Investments, measurement input	0.25		0.25
Equity Securities [Member] | Last Equity Financing [Member]
Investments, fair value	$ 2,416		$ 203
Equity Securities [Member] | Last Equity Financing [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input			0
Equity Securities [Member] | Last Equity Financing [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Investments, measurement input			1
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]
Investments, measurement input	26.93		0.41
[1]Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Note 6 - Fair Value - Assets at

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Recurring [Member]
Investments, fair value	$ 720,026	$ 458,075
Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	7,066	7,868
Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	2,788	1,359
Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	686,458	437,317
Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	29,712	20,200
Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	2,556	358
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Investments, fair value	140	155
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	140	155
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Investments, fair value	3,567	363
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	7,066	7,868
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	2,788	1,359
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	3,567	363
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	716,319	457,557
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Investments, fair value	716,319	457,557
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member]
Investments, fair value	686,458	437,317
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]
Investments, fair value	26,145	19,837
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member]
Investments, fair value	$ 2,416	$ 203

Note 6 - Fair Value - Reconcili

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 457,557	$ 350,048
Purchase of investments	421,978	344,445
Warrants and equity received and classified as Level 3	5,672	2,681
Principal payments received on investments	(95,871)	188,010
Proceeds from sale of investments	(49,835)	50,690
Net realized (loss) gain on investments	(9,094)	(2,519)
Unrealized (depreciation) appreciation included in earnings	(6,880)	3,885
Transfer out of Level 3	(1,371)	(303)
Transfer out of debt investments	0
Other	(5,837)	(1,980)
Balance	716,319	457,557
Principal payments received on investments	95,871	(188,010)
Proceeds from sale of investments	49,835	(50,690)
Debt [Member]
Balance	437,317	333,495
Purchase of investments	421,372	344,445
Warrants and equity received and classified as Level 3	0	0
Principal payments received on investments	(95,558)	188,010
Proceeds from sale of investments	(49,371)	47,436
Net realized (loss) gain on investments	(8,221)	(5,033)
Unrealized (depreciation) appreciation included in earnings	(10,044)	1,836
Transfer out of Level 3	0	0
Transfer out of debt investments	(3,200)
Other	(5,837)	(1,980)
Balance	686,458	437,317
Principal payments received on investments	95,558	(188,010)
Proceeds from sale of investments	49,371	(47,436)
Warrant [Member]
Balance	19,837	12,736
Purchase of investments	0	0
Warrants and equity received and classified as Level 3	5,664	2,681
Principal payments received on investments	0	0
Proceeds from sale of investments	(464)	3,241
Net realized (loss) gain on investments	264	2,514
Unrealized (depreciation) appreciation included in earnings	2,215	5,218
Transfer out of Level 3	(1,371)	(71)
Transfer out of debt investments	0
Other	0	0
Balance	26,145	19,837
Principal payments received on investments	0	0
Proceeds from sale of investments	464	(3,241)
Equity Securities [Member]
Balance	203	2,117
Purchase of investments	606	0
Warrants and equity received and classified as Level 3	8	0
Principal payments received on investments	0	0
Proceeds from sale of investments	0	0
Net realized (loss) gain on investments	0	0
Unrealized (depreciation) appreciation included in earnings	(401)	(1,682)
Transfer out of Level 3	0	(232)
Transfer out of debt investments	2,000
Other	0	0
Balance	2,416	203
Principal payments received on investments	0	0
Proceeds from sale of investments	0	0
Other Investments [Member]
Balance	200	1,700
Purchase of investments	0	0
Warrants and equity received and classified as Level 3	0	0
Principal payments received on investments	(313)	0
Proceeds from sale of investments	0	13
Net realized (loss) gain on investments	(1,137)	0
Unrealized (depreciation) appreciation included in earnings	1,350	(1,487)
Transfer out of Level 3		0
Transfer out of debt investments	1,200
Other	0	0
Balance	1,300	200
Principal payments received on investments	313	0
Proceeds from sale of investments	$ 0	$ (13)

Note 7 - Borrowings (Details Te

Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands						12 Months Ended				24 Months Ended	21840 Months Ended
		Feb. 25, 2022	Jun. 22, 2021	Apr. 24, 2021	Apr. 21, 2020	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020	Jun. 04, 2020	Feb. 25, 2022	Nov. 09, 2022	Jun. 15, 2022	Mar. 30, 2021	Dec. 31, 2019	Sep. 15, 2019	Aug. 13, 2019	Jun. 19, 2019	Dec. 31, 2018	Jun. 01, 2018	Oct. 11, 2017	Sep. 29, 2017
Asset Coverage to Borrowings, Ratio, Percent						172%
Restricted Investments						$ 2,788		$ 1,359
Long-Term Debt, Gross	[1]					439,323		260,250	$ 187,625						$ 154,375				$ 127,875
Debt Instrument, Face Amount						582,573		353,000
Interest Paid, Excluding Capitalized Interest, Operating Activities						17,028		10,706	8,593
Reserve Cash Balance [Member]
Restricted Investments						$ 1,000		$ 500
Key Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature			$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity			$ 125,000
Line of Credit Facility, Advance Rate of Eligible Debt Investments			60%
Long-Term Debt, Weighted Average Interest Rate, over Time						5.33%		4.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage						0.50%
Line of Credit Facility, Current Borrowing Capacity						$ 120,000		$ 71,500
Line of Credit Facility, Remaining Borrowing Capacity						40,200		19,800
Long-Term Debt, Gross						5,000		53,500
Debt Instrument, Face Amount						$ 125,000		$ 125,000
Key Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate			3.25%
Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate						0.25%
Debt Instrument, Variable Rate						7.50%		3.25%
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 200,000			$ 100,000						$ 200,000									$ 100,000
Line of Credit Facility, Current Borrowing Capacity						$ 23,200		$ 21,200
Line of Credit Facility, Remaining Borrowing Capacity						23,200		5,700
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature					$ 200,000															$ 200,000
Line of Credit Facility, Advance Rate					67%													67%
Line of Credit Facility, Change in Maximum Borrowing Capacity		$ 100,000
Long-Term Line of Credit, Total						$ 176,800		$ 78,800
Line of Credit Facility, Interest Rate at Period End						5.57%		4.62%
Long-Term Debt, Gross						$ 176,750		$ 78,750
Debt Instrument, Face Amount						200,000		100,000
NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate											3%
Asset-backed Notes 2019 [Member]
Restricted Investments						600		900
Debt Instrument, Interest Rate, Stated Percentage																	4.21%
Long-Term Debt, Gross						42,600		70,500
Debt Instrument, Face Amount																	$ 160,000
Asset-backed Notes 2022 [Member]
Restricted Investments						1,000
Debt Instrument, Interest Rate, Stated Percentage												7.56%
Long-Term Debt, Gross						100,000		0
Debt Instrument, Face Amount						100,000		0				$ 157,800
The 6.25 % Notes Due 2022 [Member]
Debt Instrument, Interest Rate, Stated Percentage																						6.25%
Debt Instrument, Face Amount																						$ 32,500
Adittional 2022 Notes [Member]
Debt Instrument, Face Amount																					$ 4,900
The 2022 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage																6.25%
Long-Term Debt, Gross	[1]					0		0	$ 37,375						$ 37,375				$ 37,375
Debt Instrument, Convertible, Conversion Price (in dollars per share)																$ 25
Repayments of Debt				$ 37,400
Interest Paid, Excluding Capitalized Interest, Operating Activities				300
Payments of Debt Issuance Costs				$ 400
The 2026 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage														4.875%
Long-Term Debt, Gross	[1]					57,500		57,500
Debt Instrument, Face Amount						57,500		57,500						$ 57,500
The 2026 Notes Underwriter Option [Member]
Debt Instrument, Face Amount														$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)														$ 25
The 2027 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage													6.25%
Long-Term Debt, Gross						57,500	[1]	0
Debt Instrument, Face Amount						$ 57,500		$ 0					$ 50,000
The 2027 Notes Underwriter Option [Member]
Debt Instrument, Face Amount													$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)													$ 25
Minimum [Member]
Asset Coverage to Borrowings, Ratio, Percent						150%
Minimum [Member] | Key Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate			1%
Minimum [Member] | Key Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate						4.25%
Minimum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					3.55%					2.75%
Maximum [Member] | NYL Facility [Member] | USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate					5.15%					3.25%
[1]Total amount of senior securities outstanding at the end of the period presented.

Note 7 - Borrowings - Borrowing

Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands		Dec. 31, 2022		Nov. 09, 2022	Jun. 15, 2022	Dec. 31, 2021	Mar. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Total commitment		$ 582,573				$ 353,000
Balance outstanding	[1]	439,323				260,250		$ 187,625	$ 154,375	$ 127,875
Unused commitment		143,250				92,750
Unamortized debt issuance costs attributable to term borrowings		(5,245)				(2,637)
Total borrowings outstanding, net		434,078				257,613
Key Facility [Member]
Total commitment		125,000				125,000
Balance outstanding		5,000				53,500
Unused commitment		120,000				71,500
NYL Facility [Member]
Total commitment		200,000				100,000
Balance outstanding		176,750				78,750
Unused commitment		23,250				21,250
Asset-Backed Notes [Member]
Total commitment		42,573				70,500
Balance outstanding		42,573				70,500
Unused commitment		0				0
Asset-backed Notes 2022 [Member]
Total commitment		100,000		$ 157,800		0
Balance outstanding		100,000				0
Unused commitment		0				0
The 2027 Notes [Member]
Total commitment		57,500			$ 50,000	0
Balance outstanding		57,500	[1]			0
Unused commitment		0				0
The 2026 Notes [Member]
Total commitment		57,500				57,500	$ 57,500
Balance outstanding	[1]	57,500				57,500
Unused commitment		$ 0				$ 0
[1]Total amount of senior securities outstanding at the end of the period presented.

Note 7 - Borrowings - Senior Se

Note 7 - Borrowings - Senior Securities (Details) - USD ($) $ / shares in Units, $ in Thousands		Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Balance outstanding	[1]	$ 439,323		$ 260,250	$ 187,625	$ 154,375	$ 127,875
Asset Coverage Per Unit (in dollars per share)	[2]	$ 1,725		$ 1,943	$ 2,133	$ 2,192	$ 2,050
Involuntary Liquidation Preference (in dollars per share)	[3]	$ 0		$ 0	$ 0	$ 0	$ 0
Credit Facilities [Member]
Balance outstanding	[1]	$ 181,750		$ 132,250	$ 50,250	$ 17,000	$ 90,500
Asset Coverage Per Unit (in dollars per share)	[2]	$ 4,169		$ 3,823	$ 7,965	$ 19,908	$ 2,896
Involuntary Liquidation Preference (in dollars per share)	[3]	$ 0		$ 0	$ 0	$ 0	$ 0
The 2027 Notes [Member]
Balance outstanding		$ 57,500	[1]	$ 0
Asset Coverage Per Unit (in dollars per share)	[2]	$ 13,179
Involuntary Liquidation Preference (in dollars per share)	[3]	0
Average market value per unit (in dollars per share)	[4]	$ 24.09
The 2026 Notes [Member]
Balance outstanding	[1]	$ 57,500		$ 57,500
Asset Coverage Per Unit (in dollars per share)	[2]	$ 13,179		$ 8,793
Involuntary Liquidation Preference (in dollars per share)	[3]	0		0
Average market value per unit (in dollars per share)	[4]	$ 24.45		$ 25.90
The 2022 Notes [Member]
Balance outstanding	[1]	$ 0		$ 0	$ 37,375	$ 37,375	$ 37,375
Asset Coverage Per Unit (in dollars per share)	[2]	$ 0		$ 0	$ 10,708	$ 9,055	$ 7,014
Involuntary Liquidation Preference (in dollars per share)	[3]	$ 0		$ 0	0	0
Average market value per unit (in dollars per share)	[4]				$ 24.60	$ 25.53	$ 25.52
The 2022-1 Securitization [Member]
Balance outstanding	[1]	$ 100,000
Asset Coverage Per Unit (in dollars per share)	[2]	$ 7,578
Involuntary Liquidation Preference (in dollars per share)	[3]	$ 0
The 2019-1 Securitization [Member]
Balance outstanding	[1]	$ 42,573		$ 70,500	$ 100,000	$ 100,000
Asset Coverage Per Unit (in dollars per share)	[2]	$ 17,799		$ 7,171	$ 4,002	$ 3,384
Involuntary Liquidation Preference (in dollars per share)	[3]	$ 0		$ 0	$ 0	$ 0
[1]Total amount of senior securities outstanding at the end of the period presented.[2]Asset coverage per unit is the ratio of the original cost less accumulated depreciation, amortization or impairment of the Company’s total consolidated assets, less all liabilities and indebtedness not represented by senior securities, to the aggregate amount of senior securities representing indebtedness. Asset coverage per unit is expressed in terms of dollar amounts per $1,000 of indebtedness.[3]The amount which the holder of such class of senior security would be entitled upon the voluntary liquidation of the applicable issuer in preference to any security junior to it. The “ — ” in this column indicates that the SEC expressly does not require this information to be disclosed for certain types of securities.[4]Not applicable to the Company’s credit facilities, 2019-1 Securitization and 2022-1 Securitization because such securities are not registered for public trading.

Note 8 - Federal Income Tax (De

Note 8 - Federal Income Tax (Details Textual) - USD ($) $ in Millions	Dec. 31, 2022	Mar. 03, 2022	Dec. 31, 2021
Federal Excise Tax, Percent	4%	4%
Operating Loss Carryforwards	$ 18.8		$ 10.8
Sales and Excise Tax Payable	0.7		0.4
Tax Basis of Investments, Cost for Income Tax Purposes	721.2		453.8
Tax Basis of Investments, Gross, Unrealized Appreciation	18.5		13
Tax Basis of Investments, Gross, Unrealized Depreciation	$ 19.8		$ 8.7

Note 8 - Federal Income Tax - R

Note 8 - Federal Income Tax - Reconciliation of Net Increase in Net Assets to Taxable Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net increase in net assets resulting from operations	$ 21,151	$ 27,782	$ 6,364
Net unrealized appreciation on investments	(5,552)	3,205	313
Other book-tax differences	3,292	1,462	782
Change in capital loss carry forward	9,484	3,643	14,698
Taxable income before deductions for distributions	$ 39,479	$ 29,682	$ 21,531

Note 8 - Federal Income Tax - T

Note 8 - Federal Income Tax - Tax Characters of Distributions Paid (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Ordinary income	$ 31,490	$ 25,099	$ 21,592
Total	$ 31,490	$ 25,099	$ 21,592

Note 8 - Federal Income Tax - U

Note 8 - Federal Income Tax - Undistributed Ordinary Income Earnings on a Tax Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Undistributed ordinary income	$ 18,813	$ 10,825	$ 6,242
Long term capital loss carry forward	(73,055)	(63,571)	(59,928)
Unrealized appreciation	18,542	12,973	9,578
Unrealized depreciation	(19,771)	(8,738)	(8,545)
Other temporary differences	11,875	7,465	5,983
Total	$ (43,596)	$ (41,046)	$ (46,670)

Note 9 - Financial Instrument_3

Note 9 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	$ 1,761
Commitments to Extend Credit [Member]
Other Commitment, Total	$ 190,000	$ 114,500

Note 9 - Financial Instrument_4

Note 9 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Unfunded commitments, principal balance	$ 190,000
Fair value of unfunded commitment liability	1,761
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	21,000
Fair value of unfunded commitment liability	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	66
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000
Fair value of unfunded commitment liability	72
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	22,500
Fair value of unfunded commitment liability	236
Engage3, LLC [Member]
Unfunded commitments, principal balance	8,000
Fair value of unfunded commitment liability	40
Groundspeed Analytics, Inc. [Member]
Unfunded commitments, principal balance	15,000
Fair value of unfunded commitment liability	150
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	88
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	65
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	72
Optoro, Inc. [Member]
Unfunded commitments, principal balance	15,000
Fair value of unfunded commitment liability	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	158
Robin Healthcare, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	100
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	64
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	25,500
Fair value of unfunded commitment liability	105
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	9,000
Fair value of unfunded commitment liability	$ 19

Note 10 - Concentrations of C_2

Note 10 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment Concentration Risk [Member]
Concentration Risk, Percentage	23%	26%
Investment Income Concentration Risk [Member]
Concentration Risk, Percentage	15%	17%	23%

Note 11 - Distributions (Detail

Note 11 - Distributions (Details Textual) - $ / shares		9 Months Ended	12 Months Ended
	Oct. 28, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)			$ 1.25
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.11	$ 1.28	1.28	$ 1.25	$ 1.25
Taxable Earnings Per Share, Basic (in dollars per share)			1.60
Earnings Per Share, Basic, Undistributed (in dollars per share)			$ 0.68

Note 11 - Distributions - Distr

Note 11 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended	12 Months Ended
	Feb. 23, 2023	Oct. 28, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Distributions declared per share (in dollars per share)		$ 0.11	$ 1.28	$ 1.28	$ 1.25	$ 1.25
Dividends, cash			$ 29,619		$ 25,067
Dividends, shares (in shares)			55,095		28,057
Dividends, stock			$ 679		$ 460
Dividend Paid January 13, 2023 [Member] | Subsequent Event [Member]
Distributions declared per share (in dollars per share)	$ 0.11
First 10/28/2022 Dividend [Member]
Record date				Feb. 17, 2023
Payment date				Mar. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Second 10/28/2022 Dividend [Member]
Record date				Jan. 18, 2023
Payment date				Feb. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,021
Dividends, shares (in shares)				5,754
Dividends, stock				$ 74
Third 10/28/2022 Dividend [Member]
Record date				Dec. 19, 2022
Payment date				Jan. 13, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 2,978
Dividends, shares (in shares)				5,618
Dividends, stock				$ 69
Fourth 10/28/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.05
Dividends, cash				$ 1,319
Dividends, shares (in shares)				2,171
Dividends, stock				$ 27
First 7/29/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,638
Dividends, shares (in shares)				4,341
Dividends, stock				$ 57
Second 7/29/2022 Dividend [Member]
Record date				Oct. 18, 2022
Payment date				Nov. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,580
Dividends, shares (in shares)				4,621
Dividends, stock				$ 60
Third 7/29/2022 Dividend [Member]
Record date				Sep. 19, 2022
Payment date				Oct. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,558
Dividends, shares (in shares)				7,703
Dividends, stock				$ 81
First 4/29/22 Dividend [Member]
Record date				Aug. 18, 2022
Payment date				Sep. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,528
Dividends, shares (in shares)				4,925
Dividends, stock				$ 60
Second 4/29/2022 Dividend [Member]
Record date				Jul. 19, 2022
Payment date				Aug. 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,484
Dividends, shares (in shares)				3,939
Dividends, stock				$ 55
Third 4/29/2022 Dividend [Member]
Record date				Jun. 17, 2022
Payment date				Jul. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,434
Dividends, shares (in shares)				4,286
Dividends, stock				$ 51
First 2/25/2022 Dividend [Member]
Record date				May 18, 2022
Payment date				Jun. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,378
Dividends, shares (in shares)				4,428
Dividends, stock				$ 50
Second 2/25/2022 Dividend [Member]
Record date				Apr. 19, 2022
Payment date				May 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,349
Dividends, shares (in shares)				4,088
Dividends, stock				$ 49
Third 2/25/2022 Dividend [Member]
Record date				Mar. 18, 2022
Payment date				Apr. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,352
Dividends, shares (in shares)				3,221
Dividends, stock				$ 46
First 10/22/21 Dividend [Member]
Record date					Feb. 18, 2022
Payment date					Mar. 16, 2022
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,100
Dividends, shares (in shares)					3,409
Dividends, stock					$ 46
Second 10/22/21 Dividend [Member]
Record date					Jan. 19, 2022
Payment date					Feb. 16, 2022
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,096
Dividends, shares (in shares)					2,680
Dividends, stock					$ 43
Third 10/22/21 Dividend [Member]
Record date					Dec. 17, 2021
Payment date					Jan. 14, 2022
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,031
Dividends, shares (in shares)					3,417
Dividends, stock					$ 56
Fourth 10/22/21 Dividend [Member]
Record date					Nov. 18, 2021
Payment date					Dec. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.05
Dividends, cash					$ 1,013
Dividends, shares (in shares)					1,197
Dividends, stock					$ 20
First 7/23/21 Dividend [Member]
Record date					Nov. 18, 2021
Payment date					Dec. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,027
Dividends, shares (in shares)					2,395
Dividends, stock					$ 38
Second 7/23/21 Dividend [Member]
Record date					Oct. 19, 2021
Payment date					Nov. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,010
Dividends, shares (in shares)					1,907
Dividends, stock					$ 34
Third 7/23/21 Dividend [Member]
Record date					Sep. 17, 2021
Payment date					Oct. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 2,008
Dividends, shares (in shares)					2,068
Dividends, stock					$ 36
First 4/23/21 Dividend [Member]
Record date					Aug. 18, 2021
Payment date					Sep. 15, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,996
Dividends, shares (in shares)					2,041
Dividends, stock					$ 34
Second 4/23/21 Dividend [Member]
Record date					Jul. 20, 2021
Payment date					Aug. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,983
Dividends, shares (in shares)					1,937
Dividends, stock					$ 34
Third 4/23/21 Dividend [Member]
Record date					Jun. 17, 2021
Payment date					Jul. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,964
Dividends, shares (in shares)					1,888
Dividends, stock					$ 33
First 2/26/21 Dividend [Member]
Record date					May 18, 2021
Payment date					Jun. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,964
Dividends, shares (in shares)					1,671
Dividends, stock					$ 29
Second 2/26/21 Dividend [Member]
Record date					Apr. 20, 2021
Payment date					May 14, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,937
Dividends, shares (in shares)					1,794
Dividends, stock					$ 29
Third 2/26/21 Dividend [Member]
Record date					Mar. 18, 2021
Payment date					Apr. 16, 2021
Distributions declared per share (in dollars per share)					$ 0.10
Dividends, cash					$ 1,938
Dividends, shares (in shares)					1,653
Dividends, stock					$ 28

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($) $ in Thousands

1 Months Ended

12 Months Ended

Feb. 24, 2023

Feb. 14, 2023

Feb. 03, 2023

Feb. 01, 2023

Jan. 24, 2023

Jan. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Proceeds from Issuance of Common Stock

$ 84,603

$ 30,086

$ 44,611

Long-Term Debt, Gross

[1]

$ 439,323

$ 260,250

$ 187,625

$ 154,375

$ 127,875

The 2021 Equity Distribution Agreement [Member]

Stock Issued During Period, Shares, New Issues (in shares)

3,982,684

Proceeds from Issuance of Common Stock

$ 50,300

Payments of Stock Issuance Costs

$ 1,000

Subsequent Event [Member] | Britecore Holdings, Inc. [Member] | Debt Investments [Member]

Payments to Acquire Investments, Total

$ 5,000

Subsequent Event [Member] | Noodle Partners, Inc. [Member] | Debt Investments [Member]

Payments to Acquire Investments, Total

$ 20,000

Subsequent Event [Member] | Canary Medical Inc. [Member]

Repayments of Debt

$ 7,500

Subsequent Event [Member] | Unagi, Inc [Member]

Repayments of Debt

$ 3,200

Long-Term Debt, Gross

$ 2,100

Subsequent Event [Member] | Embody, Inc. [Member]

Repayments of Debt

$ 2,500

Subsequent Event [Member] | Asset Purchase Agreement with CVKD [Member] | HESP LLC [Member]

Asset Purchase Agreement, Number of Shares Received in IPO (in shares)

600,000

Subsequent Event [Member] | The 2021 Equity Distribution Agreement [Member]

Stock Issued During Period, Shares, New Issues (in shares)

555,654

Proceeds from Issuance of Common Stock

$ 6,600

Payments of Stock Issuance Costs

$ 100

[1]Total amount of senior securities outstanding at the end of the period presented.

Note 13 - Financial Highlight_2

Note 13 - Financial Highlights (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Investment Company, Voluntary Fee Waived	$ 1.8	$ 1.2

Note 13 - Financial Highlight_3

Note 13 - Financial Highlights - Financial Highlights (Details) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2022 USD ($) $ / shares shares		Dec. 31, 2021 USD ($) $ / shares shares		Dec. 31, 2020 USD ($) $ / shares shares		Dec. 31, 2019 USD ($) $ / shares shares		Dec. 31, 2018 USD ($) $ / shares shares
Net asset value at beginning of period (in dollars per share)		$ 11.56		$ 11.02		$ 11.83		$ 11.64		$ 11.72
Net investment income (in dollars per share)		1.46		1.41		1.18		1.52		1.20
Realized loss (gain) (in dollars per share)		$ (0.38)		$ (0.18)		$ (0.84)		$ (0.31)		$ 0.06
Unrealized (depreciation) appreciation on investments		(0.22)		0.16		0.02		0.24		(0.13)
Net increase in net assets resulting from operations (in dollars per share)		$ 0.86		$ 1.39		$ 0.36		$ 1.45		$ 1.13
Distributions declared (in dollars per share)	[1]	$ (1.28)		$ (1.25)		$ (1.25)		$ (1.20)		$ (1.20)
From net investment income		(1.28)		(1.25)		(1.25)		(1.20)		(1.20)
From net realized gain on investments		0		0		0		0		0
Return of capital (in dollars per share)		$ 0		$ 0		$ 0		$ 0		$ 0
Other	[2]	0.33		0.40		0.08		(0.06)		(0.01)
Net asset value at end of period (in dollars per share)		$ 11.47		$ 11.56		$ 11.02		$ 11.83		$ 11.64
Per share market value, beginning of period (in dollars per share)		15.92		13.24		12.93		11.25		11.22
Per share market value, end of period (in dollars per share)		$ 11.60		$ 15.92		$ 13.24		$ 12.93		$ 11.25
Total return based on a market value (3)	[3]	(19.30%)		29.70%		12.10%		25.60%		11%
Shares outstanding at end of period (in shares) | shares		27,753,373		21,217,460		19,286,356		15,563,290		11,535,129
Expenses without incentive value		11.50%		10.50%		10%		10.80%		10.40%
Incentive fees		2.60%		3.10%		2.60%		3.20%		2.40%
Net expenses		14.10%		13.60%		12.60%		14%		12.80%
Net investment income with incentive fees		12.10%		12.20%		10.40%		12.80%		10.30%
Expenses without incentive value	[4]	11.50%		10.50%		10%		10.80%		10.40%
Incentive fees		2.60%		3.10%		2.60%		4.40%		3.30%
Net expenses	[4]	14.10%		13.60%		12.60%		15.20%		13.70%
Net investment income with incentive fees	[4]	12.10%		12.20%		10.40%		11.60%		9.40%
Net assets at the end of the period | $		$ 318,448		$ 245,335		$ 212,597		$ 184,055		$ 134,257
Average net asset value | $		$ 299,182		$ 231,215		$ 199,302		$ 160,008		$ 134,364
Average debt per share (in dollars per share)		$ 13.70		$ 11.27		$ 9.97		$ 10.05		$ 8.62
Portfolio turnover ratio		14.6	[5]	45.4	[5]	38.7	[5]	82	[6]	50.4	[6]
[1]Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.[2]Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.[3]The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.[4]During the years ended December 31, 2019 and 2018, the Advisor waived $1.8 million and $1.2 million, respectively, of incentive fee.[5]Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance[6]Calculated by dividing net debt investment purchases by the monthly average debt investment balance.

Note 14 - Summarized Financia_3

Note 14 - Summarized Financial Information for HSLFI - Statements of Operations (Details) - USD ($) $ in Thousands	4 Months Ended	12 Months Ended			16 Months Ended
	Apr. 21, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 21, 2021
Interest income on investments		$ 77,366	$ 54,411	$ 42,192
Total investment income		79,191	60,015	46,035
Interest expense		19,202	12,034	9,673
General and administrative		1,459	1,511	1,190
Total expenses		42,289	31,394	25,064
Net investment income		36,187	28,220	20,749
Net realized gain on investments		(9,484)	(3,248)	(14,698)
Net unrealized appreciation on investments		(5,552)	3,205	313
Net realized and unrealized loss on investments		(15,036)	(438)	(14,385)
Net increase in net assets resulting from operations		$ 21,151	$ 27,782	$ 6,364
HSLFI [Member]
Interest income on investments	$ 1,353				$ 1,353
Prepayment fee income					112
Total investment income	1,465				1,465
Interest expense					1,165
General and administrative					64
Total expenses	1,229				1,229
Net investment income	236				236
Net realized gain on investments	120				120
Net unrealized appreciation on investments	(392)				(392)
Net realized and unrealized loss on investments					(272)
Net increase in net assets resulting from operations	$ (36)				$ (36)